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CHARACTERIZATION OF A MUTANT ONCOLYTIC ADENOVIRUS AND THE 
ROLE OF JNK IN ENHANCING VIROTHERAPY  
Stephen L. Wechman 
February 8, 2017 
Oncolytic adenoviruses (Ads) have great therapeutic potential for lung cancer 
treatment. Cancer selective E1b-deleted Ads are safe; however, their clinical 
cancer therapeutic efficacy remains limited. The limited efficacy of Ad virotherapy 
is due to many factors including inefficient cancer cell lysis, Ad release and 
spread. Progress in overcoming these barriers to Ad virotherapy are hampered 
by limited knowledge of the genes associated with enhanced Ad release and 
spread and the dearth of understanding of the mechanisms by which E1b-
deleted Ads cause cancer cell lysis. The role of c-JNK n- terminal kinase (JNK) 
phosphorylation in this process remains unknown. By uncovering the molecular 
aspects that enhance Ad spread and oncolysis, this dissertation has addressed 
critical gaps in the oncolytic Ad field. In chapter II, the novel oncolytic Ad mutant, 
AdUV, was developed. AdUV displayed enhanced oncolytic effects, release, and 
spread in A549 cells. AdUV also induced autophagy more effectively than the 
parental strain Ad5. In chapter III, AdUV was subjected to DNA sequence 
analysis to determine which AdUV mutations may have induced these enhanced 
cancer therapeutic effects (spread, Ad release, and oncolysis). For example, 
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mutations to the DNA-binding genes 52K and pV may have enhanced AdUV 
release. These mutations increased the number of encoded positively-charged 
amino acids in AdUV. Therefore, I hypothesized that these mutations may have 
increased AdUV’s binding affinity for the negatively-charged DNA sugar-
phosphate backbone. In chapter IV, the mechanism of Ad-induced JNK 
phosphorylation was investigated to further characterize Ad oncolysis. These 
data indicated that Ads induce p-JNK via the expression of E1b-19K and E1a. 
Additionally, we have shown that the p-JNK inducer, etoposide, enhanced 
oncolytic effects, but not the replication of AdUV in vitro. This work has advanced 
the knowledge of Ad oncolysis and will lead to further progress in the field of 
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1.1 – Lung cancer 
Lung cancer is the leading cause of death from malignancy. The 
number of lung cancer deaths (158,140) in 2016 was comparable to the 
number of deaths (157,548) from the next four leading cancers combined: 
colon, breast, pancreatic and prostate (American Cancer Society). The 
Surveillance Epidemiology and End Results (SEER) statistics indicate that the 
five-year survival rate of lung cancer patients improved from 11.4% in 1975 to 
17.5% in 2006. However, lung cancer will continue to be a leading cause of 
death from malignancy unless more effective treatments are developed. 
Surgery remains the best treatment option for early stage (Stage I and 
II) lung cancer. Most stage I and II lung tumors are minimally invasive, 
therefore lobar resection is feasible for these patients. When primary lung 
tumors are resected, 85% of stage I and 77% of stage II cancer patients 
survive at least two years after diagnosis [1]. However, patient follow-up is 
necessary to observe for recurrent primary or metastatic tumor growth 




stage I, are also frequently treated with adjuvant platinum-based 
chemotherapy [2].  
For lung cancer patients with disease beyond stage II, the combination 
of surgery, intravenous (IV) chemotherapy, and radiation provides the best 
results [3-5]. Stage III lung tumors have regionally metastasized to the lymph 
nodes and often have invaded at least one of the tissues surrounding the 
lung, including the chest wall, pleura, or the main bronchus [6]. Stage IV lung 
tumors can be of any size however, distant metastasis are observed [6]. 
These distant metastases are often observed in the adrenal glands, bone, the 
opposite lung, liver or brain [7, 8]. The majority (57%) of lung cancer patients 
have distant metastases at the time of diagnosis. Therefore, most lung cancer 
patients are stage IV and are ineligible for surgery. Alternative treatments to 
surgery such as cancer chemotherapy have not significantly enhanced lung 
cancer patient survival despite the investigation of several different 
chemotherapeutic combinations [9-11]. To treat lung cancer patients more 
effectively, the development of novel cancer therapeutics is imperative. 
1.2 – Oncolytic Virotherapy 
The use of cancer selective viruses, or oncolytic virotherapy, is an 
emerging lung cancer treatment option with great therapeutic potential [12, 




tumors following their initial infection of a small number of tumor cells [12, 14]. 
The cancer selective (oncolytic) adenovirus (Ad) dl1520 displayed favorable 
safety and induced anti-tumor responses during preclinical and clinical studies 
[15-17]. To date, two oncolytic viruses have been approved for the treatment 
of cancer. First, a virus very similar to dl1520, H101, was commercially 
approved in China for the treatment of head and neck cancers in combination 
with the PF chemotherapy regimen (cisplatin and fluorouracil) by the China 
Food and Drug Administration (CFDA) [18]. In a phase III trial, H101 
increased the tumor response rate of head and neck cancer patients treated 
with the PF regimen from 39.6% to 78.8% [19]. Secondly, the United States 
Food and Drug Administration (FDA) approved the oncolytic herpes virus T-
Vec, which expresses the immune stimulatory cytokine granulocyte 
macrophage colony stimulation factor (GMCSF) for the treatment of malignant 
melanoma [20]. Interestingly, both oncolytic virus replication and the 
expression of GMCSF contributed to T-Vec’s cancer therapeutic efficacy [20]. 
Novel oncolytic Ads, such as ColoAd1, are also currently under investigation 
in a phase II clinical trials and have shown great cancer therapeutic potential 
[21]. Next generation ColoAd1 vectors feature Ad3/11 capsid chimeras which 
were shown to have the greatest cancer therapeutic activity and stability in 




capsid proteins (Enadenotucirev) appears to be safe and effective following 
intravenous (IV) injection for the treatment of distant metastases [22].  
1.3 – Human adenoviruses 
The Ad genome is composed of linear, double-stranded DNA of 
approximately 36 kb, which can be divided into early (E) and late (L) genes 
based upon their expression across the infection cycle [23, 24]. The L genes 
encode structural proteins, which package the viral DNA into the Ad virion 
during the final stages of replication. The E genes include E1a, E1b, E2, E3, 
and E4 for regulation of viral replication. The proteins encoded by E1a are 
produced immediately after infection to modulate the cell cycle, recruit cellular 
proteins, and regulate the expression of cellular and viral genes [25]. The Ad 
E1b gene encodes two major polypeptides, termed 55K and 19K, which are 
55 kilodaltons (kDa) and 19 kDa, respectively. The expression of both 
E1b55K and E1b19K is required to transform rodent cells following viral 
transduction and DNA transfection [26, 27]. Both E1B55K and E1B19K 
proteins protect infected cells from E1A-induced stabilization of TP53 and 
apoptosis [28]. E1B55K also enhances viral E1a expression [29], and is 
involved in the induction of cyclin E gene expression (which is required for 
efficient Ad replication) [30-35]. The Ad E1B19K protein is a putative B-cell 




apoptosis [36-38]. E1B19K prevents E1A-induced apoptosis by interfering 
with the actions of the pro-apoptotic proteins Bak and Bax [39]. E1B19K can 
also transactivate E1a during Ad infection [40]. Therefore, the actions of these 
E1b-encoded proteins are thought to maximize Ad replication. 
1.4 – E1b55K-deleted adenoviruses 
The E1b-55K gene has been shown to bind promyelocytic leukemia 
protein nuclear bodies (PML-nb) and TP53 during Ad infection [41-43]. By 
interacting with PML-nbs and TP53, E1b-55K was shown to induce TP53 
sumoylation as the overexpression of PML-nb and TP53 led to the 
polyubiqitination and proteolytic degradation of TP53 [44]. Dr. Arnold Berk 
applied this understanding of E1b-55K and TP53, to design the first E1b55K-
deleted oncolytic Ad, dl1520 in collaboration with Dr. Douglas Barker [26].  
This adenovirus, dl1520, was E1b55K-deleted and was hypothesized 
to be replication-deficient in primary cells expressing TP53 [45]. TP53 is the 
most commonly inactivated tumor suppressor as a result of oncogenic 
transformation. TP53 is mutated or deleted in approximately 50% of all human 
tumors [46]. This dependence upon TP53 inactivation appeared to have led to 
cancer selective cell lysis in vitro. However, Harada and Berk then tested the 
dependence of dl1520 upon TP53 inactivation to induce its oncolytic effects. 




expression via a temperature-sensitive promotor (H1299-tsp53), dl1520-
induced H1299 CPE did not correlate with the expression of TP53 [47]. These 
data suggested that the cancer selectivity of dl1520 follows a TP53-
independent mechanism of action.  
Recent studies have indicated that E1b55K-deleted Ads can only 
replicate in S-phase synchronized cancer cells [31]. E1b-55K has been 
previously shown to induce cyclin E production and cyclin dependent kinase 2 
(CDK2) phosphorylation [33]. Cyclin E overexpression is occurs in more than 
90% of lung, liver, and gastrointestinal cancers, and in more than 80% of 
glioma/blastoma, bone, and breast cancers respectively [48]. Interestingly, 
E1b-deleted oncolytic Ads were only shown to induce cyclin E and p-CDK2 in 
malignant cells. These data indicated that the oncogenic transformation(s) 
may have led to the production of E1b55K-like factors which appear to have 
recovered the attenuated CDK2/cyclin E axis activation observed by E1b55K-
deleted Ads [29]. Furthermore, these data and additional studies also suggest 
that dysregulated cyclin E production may contribute to the mechanism of 
E1b55K-deleted Ad cancer selectivity [30].  
While the true mechanism of E1b55K-deleted oncolytic Ad cancer 
selectivity remains unknown, dl1520 was safely utilized to treat several 




However, while dl1520 progressed to phase III clinical trials in combination 
with cancer chemotherapy, the trial was suspended due to the limited cancer 
therapeutic effects [18]. While E1b-deleted Ads, such as dl1520, were less 
successful than expected clinically, these trials indicated that oncolytic viruses 
were safe and an attractive drug platform for the development of cancer 
therapeutics in the future.  
1.5 – Oncolytic adenoviruses as lung cancer therapeutics 
Ads are especially promising for the treatment of lung cancer. Ads 
have respiratory tropism, allowing them to very efficiently infect and spread 
throughout the lung to produce their cancer therapeutic effects [50]. Early 
stage (phase I) Ad lung cancer clinical trials indicated that high doses of 
replication deficient Ads were well tolerated by lung cancer patients. Some 
examples include the administration of a TP53-expressing Ad by 
bronchoalveolar lavage (BAL) [51] and another L523S-expressing Ad given by 
intramuscular injection (IM) [52]. 
In a phase II clinical trial, Nemunaitis et al. administered dl1520 IV at 
increasing doses to metastatic lung cancer patients [53]. Their research 
revealed that dl1520 could infect and replicate within the patients’ lung cancer 
tumors following IV injection with no serious side effects [53]. Furthermore, 




in primary lung cancer tissue in vitro and lung cancer xenograft models in vivo 
[16, 54-56]. These studies suggest that oncolytic adenovirus therapy is safe 
for the treatment of lung cancer and displays synergistic interactions in 
combination with many cancer chemotherapeutics. 
1.6 – Repeated cancer selection enhances oncolytic adenovirus efficacy 
Most oncolytic Ads are constructed with E1b deletions and/or E1a 
regulated by cancer-selective promoters. Oncolytic Ads have achieved some 
success in human clinical trials however, their efficacy has been disappointing 
[15, 18, 57-59]. It is possible that the rational design of the E1 gene (E1a and 
E1b) modified Ads is not sufficient to induce profound cancer therapeutic 
responses. Rationally designed Ads are dependent upon a nearly complete 
understanding of Ad’s virus-host interactions. Therefore, it is necessary to 
explore new approaches for the development of more effective oncolytic Ads. 
One such approach entails the use of directed evolution. Using this approach, 
Ads are exposed to DNA mutagenic agents to generate the genetic diversity 
required for directed evolution and the selection of Ads with enhanced 
oncolytic effects. Therefore, directed evolution may be capable of generating 
Ads with greater anti-cancer activity without requiring a complete 
understanding of all the virus-host interactions your Ad construct and cancer 




was UV-irradiated prior to the selection of more effective therapeutic Ads in 
cancer cells. After 72 cycles of repeated UV-irradiation and cancer selection 
AdUV was isolated by plaque purification. AdUV displayed enhanced release 
and spread between A549 cells. AdUV displayed greater anti-cancer efficacy 
than the oncolytic Ad control, Adhz60, in all cancer cell lines tested. AdUV 
also induced autophagy more effectively than either Ad5 or Adhz60 in A549 
cells. AdUV also displayed increased virus release and oncolysis in Soas-2 
cells (AdUV was selected in these cells). In addition, AdUV significantly 
suppressed the growth of A549 xenograft tumors and prolonged the survival 
of athymic nu/nu mice. These studies suggest that AdUV has potential as a 
lung cancer therapeutic agent. 
1.7 – The role of autophagy during Ad oncolysis 
Oncolytic Ads have been shown to induce several cell death pathways 
during infection such as apoptosis [63], necrosis [64] and autophagy [65, 66]. 
Autophagy represents an alternative form of programmed cell death, distinct 
from apoptosis and necrosis [67, 68]. Autophagy leads to the sequestration of 
organelles and long-lived proteins into autophagosomes, which then fuse with 
the lysosomes forming the autophagolysosome to recycle cellular 
components [69, 70]. During autophagolysosome formation, microtubule-




(16 kDa) [71]. Therefore, the LC3-II/LC3-I protein ratio correlates with the 
abundance of autophagosomes and indicates the relative level of autophagy 
induction [72, 73].  
Autophagy is activated by cell stresses such as cell starvation [74], 
DNA damage [75], chemotherapy treatment [76] and Ad infection [66]. Ads 
have been shown to induce autophagy in glioma, ovarian and lung cancer 
cells [66, 77]. Furthermore, the autophagy inhibitors 3-methyladenine (3MA) 
and bafilomycin A1 (Baf-A1) were shown to protect cancer cells from Ad 
oncolysis [66, 78]. Autophagy induction has also been shown to support Ad 
replication [66]. These studies indicate that autophagy is crucial for Ad cancer 
therapy; however, the effects of many adenovirus genes upon autophagy 
remain unknown.  
1.8 – E1b and its effects upon Ad oncolysis  
 Despite decades of pre-clinical and clinical studies, adenovirologists 
have not emphasized the investigation of the mechanism of E1b-deleted Ad 
oncolysis. Furthermore, the role of autophagy mediators such as c-JUN n-
terminal kinase (JNK) during E1b-deleted Ad oncolysis remains unclear. The 
JNKs originate from 3 genes that yield 10 isoforms via alternative mRNA 
splicing: JNK1α1, JNK1β1, JNK2α1, JNK2β1 and JNK3α1 which represent 




which represent the 54 kDa isoforms respectively [79]. The first publication, to 
my knowledge, to demonstrate an interaction between E1b and JNK was 
published by See and Shi in 1998. However, this report did not indicate if JNK 
had an effect upon adenovirus replication or oncolysis [80]. Klein et al. 
reported in 2015 that JNK expression was essential for E1b wild-type Ad 
oncolysis [81]. However, their focus was upon the necessity of JNK 
expression for Ad oncolysis and not the study of JNK phosphorylation by E1b 
and E1a or the effect of p-JNK upon Ad replication. While Klein et al. did not 
ascertain the relationship between JNK and Ad replication specifically, they 
did report co-localization of hexon and p-JNK by immunofluorescence in Ad-
infected tumor sections, indicating that Ad replication maybe associated with 
p-JNK production within tumors in vivo [81].  
 Other reports have suggested that autophagy induction by E1b wild-
type Ads occurs independently of the molecular target of rapamycin (mTOR) 
cell starvation pathway [77, 81]. Studies have demonstrated that rapamycin 
treatment induced autophagy and enhanced E1b-deleted Ad replication [55, 
66]. However autophagy induction by Ads appears to occur via the MKK7/p-
JNK/BECLIN-1 axis, perhaps due to the expression of E1b-19K [80].  
I hypothesized that E1b-deleted Ads display less efficient virus 
replication and oncolysis, at least in part, due to attenuated p-JNK production 




show that E1b-deleted Ads induce autophagy less efficiently than E1b wild-
type Ads, indicating that autophagy signaling is likely induced by E1b [66, 82]; 
however this phenomenon has remained uncharacterized. This dissertation 
determined the effects of E1a and E1b upon JNK using Ads with selective 
E1a overexpression or bearing E1b-deletions.  
The JNK pathway is driven by the mitogen activated protein kinase 
(MAPK) pathway, which interacts with a wide array of intracellular processes 
[79]. Due to this complexity, very limited tools are available to selectively 
induce p-JNK production selectively. Therefore, cancer chemotherapeutic 
drugs which have been reported to induce p-JNK production were utilized: 
etoposide [83], cytarabine [84], cycloheximide [85], and paclitaxel [86]. To 
determine the selective effects of JNK upon Ad replication and oncolysis, 
JNK1/2-siRNAs were utilized. By the completion of these studies, this 
dissertation demonstrated for the first time that p-JNK production supports not 
only Ad oncolysis, but also Ad replication. 
1.9 – Scope of the dissertation 
dl1520, the first E1b55K-deleted virus, was initially developed and 
tested in the United States. Once E1b-deleted Ads were shown to have 
limited cancer therapeutic efficacy in several clinical trials, their clinical 




similar E1b55K-deleted Ad (H101) was approved for the treatment of head 
and neck cancer patients in China [87]. Despite the success of the E1b55K-
deleted Ads, such as dl1520 and H101, the development of cancer selective 
Ads with greater cancer therapeutic efficacy is necessary.  
The work contained within this dissertation is focused upon enhancing 
the efficacy of oncolytic Ads using multiple approaches. First, the novel Ad 
mutant (AdUV) was generated using a directed evolution approach entailing 
repeated UV-irradiation and cancer selection. In chapter II, AdUV displayed 
enhanced autophagy induction, virus release and spread. Second, the AdUV 
genome was sequenced to determine which mutations might have enhanced 
its oncolytic efficiency. In chapter III, several AdUV mutations were found in 
genes encoding Ad DNA packaging functions. These mutations were 
hypothesized to enhance the DNA packaging efficiency of AdUV by the 
inclusion of more positively-charged amino acids in these DNA binding 
proteins. These mutations may have facilitated greater binding to the 
negatively-charged DNA sugar-phosphate backbone. AdUV was also shown 
to replicate within and suppress the growth of A549 tumor xenografts while 
remaining non-lethal to AdUV-treated mice.  
While Ads have been extensively researched, the mechanism of Ad-




enhance Ad therapy remain unknown. Therefore the third approach in this 
dissertation to enhance Ad therapy, I expanded upon the literature’s 
description of Ad induced JNK phosphorylation and determined if p-JNK 
production enhanced Ad oncolysis [80, 88]. In chapter IV, E1b-deleted Ads 
displayed less p-JNK, which appeared to be induced by E1b-19K. These data 
indicated that E1a led to increased p-JNK production. The cancer 
chemotherapeutic, etoposide, was shown to induce p-JNK and enhance Ad 
oncolysis. JNK1/2-targeting siRNA confirmed that JNK was essential for Ad 
replication and A549 cell oncolysis. 
Ultimately, by uncovering Ad genes associated with increased Ad 
spread and understanding how Ads interact with the JNK pathway may help 
to overcome the limitations facing Ad oncolytic virotherapy and lead to 












DEVELOPMENT OF AN ONCOLYTIC ADENOVIRUS WITH ENHANCED 
SPREAD ABILITY THROUGH REPEATED UV IRRADIATION AND CANCER 
SELECTION 
2.1 – Introduction 
Human Ads have been modified to selectively replicate and lyse cancer 
cells [89]. Ads exhibit their favorable safety profile because they only cause 
negligible flu-like symptoms and cannot integrate their genomes into the host 
cell chromosomes [23]. The therapeutic effects of oncolytic Ads are initiated 
from a small number of infected cancer cells from which the progeny viruses 
are released to infect adjacent cancer cells further within tumors [12, 14]. 
However, preclinical and clinical studies have suggested that Ad spread is 
restricted in large tumors, limiting their therapeutic efficacy. 
The development of oncolytic Ads has focused primarily upon the 
genetic manipulation of E1a and E1b. At least two approaches have been 
applied for the development of oncolytic Ads to date. One approach is to 
delete or attenuate E1b, the expression of which is not essential for virus 
replication in cancer cells. For example, dl1520 (ONYX-015) is a gene-




mutation in the E1b region which generates a premature stop codon, 
preventing the complete translation of the E1B55K protein; therefore, dl1520 
is functionally E1b55K-deleted [15, 26, 90]. Several hundred cancer patients 
were treated with dl1520 via various routes of administration in phase I and II 
clinical trials [49]. However, during a phase III clinical trial when dl1520 was 
combined with cancer chemotherapy to treat head and neck squamous cell 
carcinoma patients, the trial was suspended due to the limited therapeutic 
effects [18].  
Another approach to develop cancer selective Ads is to regulate the 
transcription of essential viral genes, such as E1a, with tumor-specific 
promoters to restrict the expression of viral regulatory genes and oncolytic 
Ads within tumors rather than normal tissue [14, 91]. Ad-cycE was recently 
developed and expresses E1a under the control of the cyclinE promoter to 
produce cancer selective oncolytic effects [34, 35, 55]. Furthermore, the 
replication of Ad-cycE is further stimulated by Ad infection, augmenting the 
oncolytic efficacy of Ad-cycE [30, 31]. Ad-cycE can selectively replicate in a 
diverse range of cancer cells and was shown to significantly repress tumor 
growth, prolonging the survival of xenograft tumor bearing mice [34, 55]. 
Other examples of oncolytic Ads with cancer-selective promoters include, 
OBP-301 (Telomelysin®) which expresses E1a under the control of the 




which expresses E1a under the control of the prostate-specific antigen (PSA) 
promoter [93]. Both Telomelysin® and CV706 have progressed to human 
clinical trials but have shown limited cancer therapeutic efficacy. 
Although Ads with E1b deletions and/or E1a regulated by cancer-
selective promoters have achieved some success in human clinical trials, the 
efficacy of oncolytic Ad virotherapy overall has been disappointing [15, 18, 57-
59]. Oncolytic Ads were previously shown efficiently inhibit the growth of only 
small tumors in vivo following intratumoral (IT) injection [59]. This 
phenomenon was also observed during clinical studies, as the direct injection 
of dl1520 did not inhibit the growth of larger tumors clinically [15, 58]. 
Restricted virus spread in larger tumors likely presents a significant barrier to 
the efficacy of Ad virotherapy [94]. It appears that extensive genetic 
manipulation of E1a and/or E1b is not sufficient to overcome these Ad 
therapeutic barriers. Therefore, it is necessary to explore new approaches to 
develop more effective oncolytic Ads. 
In this study, the E1 wild-type dl309 (Ad5) was UV irradiated, followed 
by repeated selection in Soas-2 cancer cells. These treatments were repeated 
for total 72 cycles to select for Ads which can efficiently release from and 
spread between cancer cells. This approach targeted the entire genome 




oncolytic virus AdUV was isolated. AdUV displayed the properties of 























2.2 – Materials and Methods 
Cell Lines and Culture Conditions 
HEK293 (ATCC no. CRL-1573) human embryonic kidney cells, MRC5 
(ATTCC no. CCL-171) human non-cancerous fibroblasts, HBEC (ATTCC no. 
CRL-4051) human non-cancerous epithelial cells, A549 (ATCC no. CCL-185) 
human lung carcinoma cells, H1299 (ATCC no. CRL-5803) metastatic human 
lung carcinoma cells isolated from lymph nodes, H441 (ATCC no. HTB-174) 
human lung papillary adenocarcinoma cells, MCF-7 (ATCC no. HTB-22) 
human breast adenocarcinoma cells, and Saos-2 human bone osteosarcoma 
cells (ATTCC no. HTB-85) were obtained from the American Type Culture 
Collection (Rockville, MD, USA). A549, MCF-7, MRC5, and HEK293 cells 
were maintained in DMEM. H1299 and H441 cells were cultured in RPMI 
1640 medium. Saos-2 cells were maintained in McCoy’s 5A media. HBEC 
cells were maintained in keratinocyte serum-free medium containing bovine 
pituitary extract and recombinant epidermal growth factor (Invitrogen, 
Waltham, MA, USA). All cell culture media were supplemented with 10% fetal 
bovine serum, 5% L-glutamine, and 5% penicillin/streptomycin (100 U/mL) 
unless indicated otherwise. All cells were cultured and maintained in humidified 
5% CO2 incubators at 37 °C. All other cell culture reagents were obtained from 






Ad5, dl309, is E1 wild-type virus [95] and was used as a non-selective 
Ad control. Adhz60 with a deletion of the entire E1b gene was used as a 
cancer selective Ad control [96]. AdGFP is an Ad vector with the entire E1 
gene (E1a and E1b) deleted, expressing GFP driven by the cytomegalovirus 
(CMV) promoter. AdGFP, as a negative control, does not replicate nor induce 
CPE. All Ads used in this study are based on the Ad5 backbone sequence. 
To select for Ads with increased spread, cell culture media containing 
Ad5 dl309 was UV-irradiated for 5 min using a UV-light germicidal lamp, 
inactivating approximately 90% of virus particles. The UV-light source was a 
germicidal lamp, USEG30T3 (Sylvania, Danvers, MA, USA), fitted with a 30 
watt G30T8 UV-light bulb (Philips, Amsterdam, The Netherlands), which 
produces UV type-C irradiation. UV irradiation was measured with a 25X UVX 
radiometer (Fisher Scientific, Pittsburgh, PA, USA). Using these conditions, 
213 μW/cm2 UV type-C was produced, generating a total UV dose of 639 J/m2 
after 5 min exposure. Irradiated viruses were then used to infect Saos-2 
cancer cells, in which Ads cannot efficiently replicate [31]. Four h after 
infection, extracellular virus particles were removed by washing the cells with 
fresh media. The cell culture media were collected at the first sign of CPE, 
generally at 24 h after infection, to harvest viruses that might replicate and 
release from the infected cancer cells more efficenctly. The harvested viruses 
were then amplified in 293 cells before being used for another cycle of UV-
irradiation. These treatments were repeated for total 72 cycles and AdUV, that 






Reprinted with permission: Wechman et al., Viruses, 2016 
Figure 1. The repeated UV irradiation and cancer selection of 
AdUV. Ad5 dl309 was initially amplified in HEK293 cells prior to UV-
irradiation. Irradiated viruses (dl309IR) were then selected in Saos-2 
cancer cells. Viruses were then harvested from Saos-2 cells and 
amplified in HEK293 cells before subsequent cycles of UV irradiation. 
After 72 cycles of UV irradiation and cancer selection, AdUV was 







Virus Titration and Release 
Virus titer was determined using the TCID50 method as described 
previously [33]. HEK293 cells were seeded overnight onto 96-well plates at a 
density of 1 × 103 cells per well and infected with virus samples serially diluted 
10 fold. The presence or absence of CPE in HEK293 cells was then recorded 
after a minimum of 7 days to calculate the virus titer. 
To determine the release kinetics of AdUV, A549 cells were seeded 
onto 12-well plates at a density of 1 × 105 cells per well. A549 cells were then 
infected with Ad5, Adhz60 or AdUV at an MOI of 1. Samples were collected at 
6, 24, 36, 48, and 72 h after infection. The cells and cell culture media were 
separated by centrifugation at 2000 RPM (350 RCF) at 4 °C for 5 min using a 
micromax RF refrigerated microcentrifuge equipped with an IEC 851 rotor 
(Thermo Fisher Scientific, Waltham, MA, USA). Cell pellets were then 
resuspended in 1 mL of sterile phosphate buffered saline (PBS) and 
subjected to 3 freeze-thaw cycles to release viruses contained within cells 
prior to titration. Cell free media samples were titered to detect viruses 
released from cells. For studies focusing upon virus titer in the media alone, 
cells were infected at 1 MOI and media samples (20 μL) were collected daily 








Western Blot Analysis 
A549 cells were seeded onto 60 mm dishes at a density of 6 × 105 cells 
per dish incubated overnight. Cells were collected and centrifuged at 1500 
RPM (453 RCF) at 4 °C for 5 min using an Eppendorf 15 amp 5810 R 
refrigerated centrifuge equipped with a A-4-62 rotor (Eppendorf, Hamburg, 
Germany). The cell pellets were then washed with PBS prior to lysis with radio 
immunoprecipitation assay (RIPA) buffer containing 50 mM Tris-HCl, 150 mM 
NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% sodium docecyl 
sulfate (SDS) with a protease inhibitor (PI) cocktail containing 4-(2-
aminoethyl)-benzenesulfonyl fluoride (AEBSF), pepstatin A, trans-
epoxysuccinyl-L-leucylamido-(4-guanidino)butane (E-64), bestatin, leupeptin, 
and aprotinin (10 mL / 1 × 106 cells; Sigma, St. Louis, MO, USA). The cell 
lysates were then incubated on ice in PI containing RIPA buffer for 30 min and 
homogenized every 10 min using a vortex-genie 2 (Scientific Industries, 
Bohemia, NY, USA). These lysates were then centrifuged at 14,500 RPM 
(196,000 RCF) at 4 °C for 10 min using a micromax RF microcentrifuge 
equipped with an IEC 851 rotor to pellet cell debris formed during lysate 
preparation (Thermo Fisher Scientific, Waltham, MA, USA). The pellet was 
discarded and the supernatant was stored at −80 °C for further 
experimentation. Protein concentrations were determined using the Pierce 
BCA protein assay kit according to the manufacturer’s instructions (Thermo 
Fisher Scientific, Waltham, MA, USA). Equal amounts of cellular protein were 
resolved by electrophoresis through 8% (E1A, hexon, penton, protein V, 
protein VI, protein VII) or 12% (LC3-I and LC3-II) SDS-polyacrylamide gels 




Little Chalfont, UK) using a semi-dry transfer apparatus (BIO-RAD, Hercules, 
CA, USA). Membranes were then blocked using 5% nonfat milk prepared in 
TBST for 1 h at room temperature. To detect protein expression, membranes 
were incubated with the following primary antibodies: rabbit-anti-adenovirus 
type 5 (1:10,000; Abcam, Cambridge, UK), rabbit-anti-human-LC3 (1:3000; 
Novus Biologicals, Littleton, CO, USA), rabbit-anti-human-actin (1:2000; 
Sigma, St. Louis, MO, USA) or mouse-anti-adenovirus-E1A antibody (1:1000; 
BD Pharmagen, San Jose, CA, USA) at 4 °C overnight on a lab-line thermal 
rocker (Thermo Fisher Scientific, Waltham, MA, USA). Primary antibody 
binding was detected by the incubation with the horseradish peroxidase 
(HRP) linked anti-mouse or anti-rabbit immunoglobulin (Ig) diluted 1:5000 for 
1 h at room temperature (Amersham, Piscataway, NJ, USA). All antibodies 
were diluted in TBST. Enhanced chemiluminescence (ECL) reagents were 
used to detect HRP-linked secondary antibody binding according to the 












Plaque Formation Assay 
A549 cells were seeded onto 6-well plates at a density of 3 × 105 cells 
per well. Cells were then infected with Ad5, Adhz60 and AdUV at an MOI of 
0.01. The cell culture media were removed after 6 h and replaced with 5 mL of 
sterile DMEM, 1% agarose heated gell per well. This gell overlay was then 
allowed to become solid at RT. Images were taken 6 days post-infection with 
an EVOS FL microscope (Life Technologies, Carlsbad, CA, USA) at 4× total 
magnification. The pixels contained within 10 representative plaques per Ad5, 
Adhz60, and AdUV treatment groups were quantified with the area density 
tool using Gel-pro analyzer 4.0 software according to the manufacturer’s 
tutorial (Media Cybernetics, Rockville, MD, USA). The total number of pixels 
for each plaque was converted to millimeters squared (mm2) by dividing the 
number of pixels per plaque by the number of pixels per 1 mm2 (261,100 













Quantification of Band Intensity 
Band intensities were quantified by Gel-pro analyzer 4.0 software in 
accordance with the manufacturer’s tutorial (Media Cybernetics, Rockville, 
MD, USA). Densitometric values were expressed as the absolute integrated 
optical density (IOD) of each band normalized to actin expression as 
described previously [55]. Mock treated cells were represented as 1 fold LC3-

















Cells were seeded overnight at a density of 2 × 104 (H1299), 2.5 × 104 
(MRC5), 3 × 104 (HBEC), 3 × 104 (A549), 4 × 104 (MCF-7), or 6 × 104 (H441) 
cells per well in 24-well plates. Cytotoxicity was assessed by crystal violet 
staining [97]. Suspended cells were removed by aspiration, the remaining 
adherent cells were then fixed with 3.7% formaldehyde for 20 min at room 
temperature. The excess formaldehyde was washed off with PBS; the cells 
were then stained using 1% crystal violet at room temperature for 30 min. 
Excess crystal violet was washed away with water. Plates were then scanned 
using an HP Scanjet 4070 scanner (HP, Palo Alto, CA, USA). The remaining 
crystal violet was then solubilized with a 2% SDS solution and the sample 
absorbances (OD) were measured at 590 nm using a Synergy HT Multi-Mode 
Microplate Reader (Bio-Tek, Winooski, VT, USA). The OD values of each 
treatment were then normalized to mock-treated cells converting each sample 
OD into the percent (%) of cell viability according to the formula, cell viability 
% = (OD of treated cells / OD of mock-treated cells) × 100%. A549 cells 
displaying CPE were photographed at 200× magnification using an Olympus 










All experiments were repeated at least 3 times. Quantification of results 
was reported as means of 3 independent experiments plus or minus (±) the 
standard deviation. The Pearson correlation coefficient (r) was used to 
evaluate the accuracy of equations used to calculate sample protein 
concentrations with the Pierce BCA protein assay kit. Statistical significance 
was assessed using analysis of variance analysis (ANOVA) for parametric 
data and the Kruskal-Wallis test for non-parametric data. Multiple 
comparisons of ANOVA tests were corrected using Bonferroni’s method. 
Multiple comparisons of Kruskal-Wallis one-way analyses were corrected by 
Dunnett’s test. All statistical tests were conducted using GraphPad PRISM 6 













2.3 - Results 
AdUV Displays More Efficient Release and Cancer Cell Lysis 
AdUV was generated as illustrated in Figure 1. Briefly, AdUV was 
isolated from a pool of dl309 (Ad5) viral particles that were repeatedly treated 
with UV irradiation and selected in cancer cells for 72 cycles. To evaluate the 
potency of AdUV in lung cancer cells, A549 cells were infected with the 
increasing MOIs of AdGFP, Ad5, Adhz60, or AdUV for 5 days (Figure 2A). 
The differences among treatment groups were greatest at an MOI of 3; these 
cancer cell viabilities were 20, 60, and 90% after treatment with AdUV, Ad5, 
or Adhz60, respectively (Figure 2B). Morphologically, AdUV induced greater 
cell rounding, consistent with CPE relative to A549 cells treated with Adhz60, 
Ad5 (Figure 2C). These data indicated that AdUV efficiently destroyed A549 












Reprinted with permission: Wechman et al., Viruses, 2016 
Figure 2. AdUV is released from and lyses A549 cells more 
efficiently than Adhz60. (A) A549 cells stained with crystal violet 
after five days’ treatment with the indicated Ads and MOIs; (B) 
Quantification of A549 cells stained with crystal violet expressed at 
the percent (%) viability; (C) CPE in A549 cells treated at an MOI of 1 




five days post-infection; (D) A549 cells were infected with at an MOI 
of 1 with Adhz60 and AdUV and media samples were collected daily 
until day 5. Ad titer was determined via the TCID50 method using 
HEK293 cells. Day 0 represents samples collected at 6 h post-
infection; (E) Crystal violet staining of non-cancerous lung fibroblasts 
(MRC5) and epithelial (HBEC) cell lines treated at an MOI of 10 for 3 
days. Quantified data are shown ± the standard deviation (SD) of 3 
independent replicates. Statistical significance was assessed relative 
to the oncolytic Ad control Adhz60 via two-way ANOVA relative to 
Adhz60 treated cells with multiple comparisons corrected for by 
Bonferroni’s method. ‡ indicates p-value < 0.001. 
The enhanced lysis of A549 cells by AdUV prompted additional studies 
to determine if AdUV was released from cells more efficiently. To determine 
the release kinetics of AdUV, A549 cells were infected with AdUV and Adhz60 
and media samples were then collected at 0, 1, 2, 3, 4, and 5 days post-
infection (Figure 2D). Viral titers were then determined to quantify the number 
of virus particles released into culture media at each time-point. The titers for 
both viruses within the cell culture media increased with time; however, AdUV 
media titers were greater at each time-point than Adhz60. At day 2, AdUV titer 
(3 × 107) was 40.5 fold greater than Adhz60 (7.4 × 105) in the cell culture 
media (Figure 2D). To evaluate the cancer selectivity of AdUV, MRC5 and 
HBEC non-cancerous cells were infected with negative control AdGFP, the 




MOI of 10. These data indicated that AdUV lysed MRC5 and HBEC non-
cancerous cells less efficiently than the cancer non-selective Ad5 however, 
AdUV lysed more non-cancerous cells than the cancer selective Adhz60; 
indicating that AdUV is at least partially cancer selective (Figure 2E). 
To verify the enhanced release and spread of AdUV, plaque assays 
were conducted. The plaque assay is based on the ability of a single 
infectious viral unit (IFU) to replicate in cells and release a large number of 
progeny that can infect neighboring cancer cells, finally forming a 
macroscopic area of cytopathology, or plaque, on a monolayer of cultured 
cells. Viruses that can efficiently replicate and release a greater number of 
viral particles will presumably form larger plaques. In this study, nearly 
confluent (70%) A549 cells were infected with Ad5, Adhz60, or AdUV. Initial 
plaque formation was observed 4 to 5 days post-infection. At day 6 post-
infection, at least 10 plaques formed by each virus were studied. The average 
size of plaques formed by Ad5, Adhz60, and AdUV were 0.883, 0.534, and 
1.680 mm2, respectively; plaques formed by AdUV were 314% larger than 
those plaques formed by Adhz60 and 190% larger than those of Ad5 (Figure 
3A,B; 2 representative plaques per treatment are shown). These differences 
were shown to be statistically significant. These studies taken together 
indicate that AdUV is released and spreads more effectively than Ad5 and 





Reprinted with permission: Wechman et al., Viruses, 2016 
Figure 3. AdUV spread in A549 cells. (A) Two representative 
plaques of Ad5, Adhz60 and AdUV treated A549 cells are shown at 
4× magnifications; (B) Using the 1000 µM scale (or 1 mM), the 
number of pixels contained within each plaque was calculated by 
dividing by the number of pixels contained within each plaque by the 
number of pixels per 1 mm2 to determine the size of each plaque in 
square millimeters (mm2). These data were then plotted as the 
average ± the SD of these 10 quantified plaques. Statistical 
significance was assessed using the Kruskal-Wallis test. Adjusted p-

























Improved AdUV Replication in Cancer Cells 
To investigate whether the large plaque formation phenotype of AdUV 
was related to increased virus replication, viral early (regulative) and late 
(structural) protein production was studied in A549 cells by Western blot 
analysis. The E1b-deleted Adhz60 produced much less E1A than the E1b 
wild-type Ad5 in A549 cells at 48 h (Figure 4A). This result was expected 
because E1b expression has been supports E1A production during Ad 
infection [29]. At 48 h, AdUV induced peak E1A production. The level of AdUV 
E1A production was even greater than the cancer non-selective wild-type Ad 
Ad5 (Figure 4A). At 72 h, the production of E1A by AdUV decreased, while 
Adhz60-mediated E1A production increased (Figure 4A). Following the rapid 
expression of E1A proteins by AdUV, late protein production was also shown 
to increase to levels much greater than Adhz60 and comparable to Ad5 at 72 












Reprinted with permission: Wechman et al., Viruses, 2016 
Figure 4. AdUV virus replication in A549 lung cancer cells. (A) 
The expression of the Ad E1A and late genes were observed in A549 
cells treated with the indicated Ads at an MOI of 1 following 6 h, 24 h, 
48 h, and 72 h infection; (B) Virus titer outside of A549 cells treated 
with the indicated Ads at an MOI of 1. Samples were collected at the 




cell culture media was 7 fold for Ad5 and 24 fold for AdUV when 
normalized to Adhz60 titer; (C) Virus titer inside of infected A549 cells 
treated with the indicated Ads at an MOI of 1. Samples were collected 
at the indicated time-points. At 36 h, the titers of both AdUV and Ad5 
inside of cells were 9 fold greater than Adhz60. Data is presented as the 
average titer ± SD of 3 independent replicates. Significance was 
determined via the Kruskal-Wallis test. Adjusted p-values were reported 
for multiple comparisons via Dunnett’s test. h indicates hours, * indicates 
p-value < 0.05. 
To study the oncolytic replication and release of AdUV further, A549 
cells were infected with AdUV, Ad5, or Adhz60 at an MOI of 1. In this 
experiment, the cell culture media and total cells were collected at 6, 24, 36, 
48, and 72 h post-infection. The cells and culture media were separated via 
centrifugation to determine the titers of Ads within cells and of viruses 
released into the culture media. The titers of AdUV released into the cell 
culture media were 5 × 106 at 36 h which was greater than both Ad5 (1.5 × 
106) and Adhz60 (1.5 × 105; Figure 4B, left). When these data were 
normalized to Adhz60 titer, AdUV was 24 fold while Ad5 titer was 7 fold 
greater than Adhz60 (Figure 4B, right). The viral titers of AdUV and Ad5 within 
cancer cells were similar; the titers of both AdUV and Ad5 were consistently 5 
to 10 fold greater than Adhz60 from 24 to 72 h within A549 cells and were 9 
fold greater than Adhz60 at 36 h (Figure 4C). These data indicate that AdUV 
replicates and is released more rapidly from A549 cells than Adhz60. It is 
likely that the rapid release of AdUV supports its ability to form large plaques 




AdUV is a Greater Autophagy Inducer 
Ads have been shown to induce autophagy to enhance virus replication 
[66]. Autophagy leads to the sequestration of organelles and long lived 
proteins into autophagosomes, which then fuse with lysosomes, forming the 
autophagolysosome to recycle cellular components [69]. During 
autophagolysosome formation, microtubule-associated protein 1 light chain 3 
(LC3) matures from LC3-I (18 kDa) to LC3-II (16 kDa) [71]. Therefore, the 
LC3-II/LC3-I protein ratio can be used to estimate the abundance of 
autophagosomes and indicate the relative levels of cellular autophagy 
induction [72, 73].  
To study autophagy induction by AdUV, A549 cells were treated with 
AdGFP, Ad5, Adhz60, or AdUV at an MOI of 1. Large vesicles were observed 
in the cytoplasm of A549 cells treated with Ad5 and AdUV, but not with 
AdGFP or Adhz60 (Figure 5A, arrowheads). The presence of such vesicles is 
a morphological marker of autophagy induction. Autophagy induction was 
evaluated further via the observation of LC3 production via Western blot 
analysis. Relative to mock, the LC3-II/LC3-I expression ratio increased to 
30.9, 12.2, and 7.8 fold for AdUV, Ad5, and Adhz60, respectively (Figure 5B). 
AdUV treatment displayed the greatest LC3-II/LC3-I fold expression ratio. 
According to these data, AdUV induced autophagy much more effectively 







Reprinted with permission: Wechman et al., Viruses, 2016 
Figure 5. AdUV induces greater autophagy in A549 cells. (A) 
Pictures of A549 cells (400× total magnifications) treated with the 
indicated Ads at an MOI of 1 for 3 days. Boxes indicate the magnified 
(~9.3× total magnifications) to emphasize the presence or absence of 
vesicle formation in the cytoplasm. Arrows were used to indicate 
these vesicles. Scale bar (top right) is indicative of 600 µm; (B) A549 
cells were treated with the indicated Ads at an MOI of 1 for 5 days 
and observed for LC3 expression by Western blot analysis. 
Densitometric analysis of LC3-II to LC3-I and actin were performed 
using Gel-pro analyzer 4.0 software. LC3 expression was normalized 






AdUV Kills a Variety of Cancer Cell Lines 
To study the oncolytic effects of AdUV upon other cancer cell lines, 
A549, H1299, and H441 lung cancer cells, as well as MCF-7 breast cancer 
cells were treated with increasing MOIs of AdGFP, Ad5, Adhz60, or AdUV for 
5 days. Cell viability was assessed via crystal violet staining and normalized 
to mock-treated cancer cells (Figure 6A). The negative control AdGFP did not 
alter treated cell viability while treatment with the positive control Ad5 was 
shown to efficiently lyse all cancer cell lines tested. AdUV lysed A549 cells 
with significantly greater efficiently than both Ad5 (p-value = 0.005) and 
Adhz60 (p-value = 0.0002) at 0.3 MOI (Figure 6A). AdUV killed H1299 lung 
cancer cells 64%, comparing with 8% of Adhz60 and 18% of Ad5 treatment at 
the same condition (0.3 MOI). Compared with the E1b-deleted Ad Adhz60, 
AdUV also efficiently destroyed H441 lung cancer cells and MCF-7 breast 
cancer cells (Figure 6A). The EC50s of AdUV were 0.99, 1.12, 1.12, and 1.76 
for A549, H1299, H441 and MCF-7, respectively (Figure 6B). Adjusted p-
values for multiple comparisons indicated that statistically significant 
differences were observed between the AdUV and Adhz60 treatment groups 
in all cancer cell lines treated at an MOI of 1 except MCF-7 (Figure 6C). 
Therefore, AdUV induced the oncolysis of multiple cancer cell lines much 






Reprinted with permission: Wechman et al., Viruses, 2016 
Figure 6. AdUV kills multiple cancer cell lines more effectively 
than Adhz60 in vitro. (A) A549, H1299, H441 lung cancer cells and 
MCF-7 breast cancer cells were treated with the indicated MOIs and 
Ads for 5 days prior to staining with crystal violet. The amount of 
crystal violet staining was quantified and expressed as the percent 
(%) viability of treated cells relative to non-treated cells ± the standard 
deviation of 3 independent experiments; (B) EC50 values were 
determined using GraphPad PRISM software; (C) Two-way ANOVA 
with multiple comparisons were conducted between all Ad treatments 




reported for multiple comparisons via Bonferroni’s method. d.n.e. 
indicates that the EC50 does not exist, * Indicates a p-value < 0.05, † 



















2.4 - Discussion 
All clinical studies have shown that the efficacy of Ad virotherapy, 
specifically dl1520/ONYX-015 and H101, has remained low [15, 17, 18, 57, 
58, 98-100]. Ad spread within solid tumors was limited to cancer cells in the 
immediate vicinity of the injection site in clusters of 5-20 cells during clinical 
studies [101-103]. In the Dr. McMasters lab, intratumorally (IT) injected Ads 
localized within capsule-like structures in syngenic xenograft bearing mice 
[35]; the formation of these capsules likely prevented Ad spread throughout 
the entire tumor mass, limiting its therapeutic outcomes. These data indicated 
that Ad spread is restricted in tumors and may have antagonized the efficacy 
of Ad virotherapy [94]. 
The development of Ad vectors with increased spread would likely lead 
to enhanced cancer therapeutic efficacy for the treatment of solid tumors. 
Most Ads used clinically are E1 gene modified. E1-modified Ads have been 
the focus of clinical studies primarily because the functions of E1 are well 
characterized relative to many of the other Ad genes, whose effects upon Ad 
replication in cancer cells are not understood. Therefore, it is difficult to predict 
the biological consequences resulting from the genetic manipulation of non-
E1 Ad genes. An alternative strategy to develop oncolytic Ads is to use 
random mutagenesis to introduce changes to the viral genome and then 




been shown to enhance the oncolytic efficacy of other viruses such as the 
recombinant Newcastle disease virus MTH87 [62] and Ad5 [60, 61]. In this 
study, dl309 (Ad5) was treated with UV irradiation and then selected from the 
pool of the UV-irradiated viruses for efficient replication in and release from 
cancer cells. This approach differs from previous reports as Ad particles were 
treated with DNA-damaging agent a total of 72 times throughout the cancer 
selection process. After 72 cycles of UV irradiation and cancer selection, 
AdUV was isolated. AdUV formed larger plaques than both Adhz60 and Ad5 
in cancer cells, indicating greater viral spread. Furthermore, AdUV displayed 
greater anti-cancer potency and efficacy in all cancer cell lines tested. These 
studies demonstrated the efficacy of AdUV in vitro. 
Previously, Ad infection was shown to increase the conversion of LC3-I 
to LC3-II, inducing autophagy, which positively correlates with enhanced viral 
replication and oncolytic cell death. This suggests that autophagy may 
generate macromolecules to support Ad assembly and replication [66]. 
Results presented in chapter II have shown that AdUV induced LC3-II 
conversion more effectively than either Ad5 or Adhz60 in cancer cells. 
Furthermore, the autophagy inducer verapamil, an L-type Ca2+ channel 
antagonist, has been shown to increase Ad spread between cancer cells in 
vitro [104], indicating that increased autophagy induction by AdUV may have 




of AdUV. The autophagy inhibitor 3MA, a phosphatidylinositol 3-kinase (PI-
3K) and autophagosome formation inhibitor, was shown to inhibit the 
replication and oncolysis of Ad infected cancer cells validating these findings 
[66]. Ad-mediated cancer cell lysis may also be related to the induction of 
apoptotic [36] and necrotic [64] cancer cell death pathways. Conflicting 
reports also indicate that wild-type serotype 5 Ads (Ad5) kill cancer cells 
independently of caspase activation and TP53 expression [64, 105]. While the 
molecular mechanism of enhanced AdUV cytolysis remains unclear, enhanced 
autophagy induction appears to play an important role. 
One limitation of this approach is that multiple mutations may be 
introduced into the viral genome. Ascertaining the effects of an individual 
mutation upon virotherapy from mutagenesis and cancer selection is complex. 
To determine which mutation or combination of mutations has the greatest 
effect upon this enhanced oncolysis phenotype, additional in vitro and in vivo 











Reprinted with permission: Wechman et al., Viruses, 2016 
Figure 7. AdUV DNA mutation map. 30 mutations were detected in 
the AdUV genome in total, relative to the Ad serotype 5 (Ad5) 
reference sequences. No mutations were present in the early genes. 
The majority of these mutations were contained in Ad late genes. 
Mutations are indicated by exclamation points. Data was collected via 















In this study, these data indicated that AdUV, developed through repeated 
mutagenesis and selection in cancer cells, has displayed many favorable 
characteristics and has substantial potential as a cancer therapeutic platform. 
The enhanced cancer cell lysis by AdUV appears to be related to the 
increased viral replication and release from infected cancer cells, as well as 
increased autophagy induction. This study has also indicated the utility of this 

















ADENOVIRUS WITH DNA PACKAGING GENE MUTATIONS INCREASED 
VIRUS RELEASE 
3.1 – Introduction 
In the preceding chapter, AdUV was isolated from a pool of the Ad 
serotype 5 dl309 (Ad5) viral particles which were repeatedly treated with UV 
type-C irradiation and selected for rapid cancer cell lysis. AdUV was shown to 
lyse cancer cells very effectively and form large viral plaques on cancer cell 
monolayers [82]. In this chapter, we extended the description of AdUV in 
Chapter II to identify AdUV genome mutations. No mutations were observed 
in the early genes (E1, E4) in AdUV, but several mutations were found within 
the late genes encoding Ad structural proteins involved in viral DNA 
packaging. AdUV was shown to effectively lyse cancer cells while safely and 
efficiently suppressing tumor growth using an athymic nude mouse (NCr-




3.2 – Materials and Methods 
Cell Lines and Culture Conditions 
HEK293 (ATCC no. CRL-1573) human embryonic kidney, MRC5 
(ATCC no. CCL-171) human non-cancerous lung fibroblast, HBEC (ATCC no. 
CRL-4051) human non-cancerous human bronchial epithelial cells, A549 
(ATCC no. CCL-185) human lung carcinoma and Saos-2 (ATCC no. HTB-85) 
human osteosarcoma cells were all purchased from the ATCC (Rockville, MD, 
USA). A549, MRC5 and HEK293 cells were maintained in Dulbecco's 
Modified Eagle's Medium (DMEM). Saos-2 cells were maintained in McCoy’s 
5A media. DMEM and McCoy’s 5A media were supplemented with 10% fetal 
bovine serum, L-glutamine, and penicillin/streptomycin (100 U/mL). HBEC 
cells were cultured in airway epithelial cell basal medium (ATCC PCS-300-
030) supplemented with bronchial epithelial cell growth kit (ATCC PCS-300-
040). All cells were cultured and maintained in humidified 5% CO2 incubators 











Ad5 dl309 is E1 wild-type [95] and was used as a non-selective Ad 
control. This virus also contains deletions in E3, preventing the expression of 
E3B10.4K, 14.6K, and 14.7K, but not the E3A glycoprotein (gp) 19K gene 
[95]. Adhz60 is an E1b-deleted vector similar to dl1520 and H101 and was 
used as a cancer selective control in these studies [96]. AdGFP is E1 (E1a 
and E1b) deleted, with green fluorescent protein (GFP) expression driven by 
the CMV promoter [55]. AdGFP, as a negative control, does not replicate nor 
induce CPE [34, 35]. All Ads used in this study express E1 and E4 unless 
otherwise specified, and are based upon Ad5 backbone sequences 
(GENEID# AC_000008.1). 
To select Ads with increased spread, Ad5 dl309 was treated with UV 
irradiation for 5 min, inactivating approximately 90% of virus particles. The 
UV-light source was a germicidal lamp, USEG30T3 (Sylvania, Danvers, MA, 
USA), fitted with a 30 watt G30T8 UV-light bulb (Philips, Amsterdam, The 
Netherlands), which produces UV type-C irradiation. UV irradiation was 
measured with a model 25X UVX radiometer (Fisher Scientific, Pittsburgh, 
PA, USA). Using these conditions, 213 μW/cm2 UV type-C was produced, 
generating a total UV dose of 639 J/m2 after 5 min exposure. Irradiated 
viruses were then used to infect Saos-2 cancer cells, in which Ads cannot 
replicate as well as in HEK293 and A549 cells [31]. Four h after infection, 
virus particles in the medium were removed by washing the cells with fresh 
media. Medium from infected monolayer cultures was collected at the first 




replicate more efficiently in and release from the infected cancer cells. The 
harvested viruses were then amplified in HEK293 cells before subsequent 
cycles of UV-light treatment. These treatments were repeated for 72 cycles. 
AdUV was then isolated from a mixture of viruses by plaque purification and 


















Virus Titration and Release 
Virus titer was determined using the median tissue culture infective 
dose (TCID50) method [33, 59, 106]. HEK293 cells were seeded overnight 
onto 96-well plates at a density of 1 × 103 cells per well and infected with virus 
samples serially diluted 10 fold. The presence or absence of CPE in HEK293 
cells was recorded, after a minimum of 7 days, to calculate Ad titer. 
To determine the release kinetics of AdUV, A549 and Saos-2 cells 
were seeded onto 12-well plates at a density of 1 × 105 and 1.5 × 105 cells per 
well, respectively. A549 cells were then infected with Ad5, Adhz60 or AdUV at 
an MOI of 1. The cells and cell culture samples were then collected at 6, 24, 
36, 48, 72, 96 and 120 h post-infection. The cells were separated from the cell 
culture media and discarded from each sample following centrifugation at 
2000 RPM (350 RCF) at 4 °C for 5 min using a micromax RF refrigerated 
microcentrifuge equipped with an IEC 851 rotor (Thermo Fisher Scientific, 
Waltham, MA, USA). The cell fraction was resuspended in PBS and subjected 
to 3 freeze and thaw cycles to release all Ads from the infected cancer cells. 
Cell free media samples and lysed cell samples were titered to detect the 








Cells were seeded at a density of 3 × 104 (A549) or 4.5 × 104 (Saos-2) 
cells per well onto 24-well plates and allowed to adhere overnight. Cytotoxicity 
was assessed by crystal violet staining after 5 days [97]. Suspended cells 
were aspirated and the adherent cells were then fixed via incubation with 
3.7% formaldehyde for 25 min at room temperature (RT). Excess 
formaldehyde was washed away using PBS. Cells were then stained using 
1% crystal violet for 30 min at RT. Excess crystal violet was washed away 
with water. These crystal violet stained wells were then scanned using an HP 
Scanjet 4070 scanner (HP, Palo Alto, CA, USA). The remaining crystal violet 
was then solubilized with a 2% SDS solution and the sample ODs were 
measured at 590 nm using a Synergy HT Multi-Mode Microplate Reader (Bio-
Tek, Winooski, VT, USA). These OD values were then normalized to mock-
treated cells converting each sample OD into the percent (%) cell viability by 












DNA sequencing was performed at the University of Louisville 
(Louisville, KY, USA) Genomics Facility using Ion Torrent PGM Sequencing 
200 kit v2 and Ion Torrent PGM system. An Ion 314 v2 Chip was used for 
loading the enriched Ion One Touch 200 ISP samples. Open source 
integrated genomics viewer (IGV) software was downloaded to view these 
DNA sequencing data. Mutations with low DNA sequencing error rates are 


















Lung Cancer Xenograft 
Female athymic nude mice (NCr-nu/nu) were obtained from the 
National Cancer Institute (Bethesda, MD, USA). Tumors were formed 
following the subcutaneous injection (SC) of 5 × 106 A549 lung cancer cells 
into the right flanks of NCr-nu/nu mice at 6 weeks of age. Ads were titrated on 
HEK293 cells using the plaque assay to determine the plaque forming units 
(PFU) for AdUV and AdGFP prior to intratumoral injection as described 
previously [107]. Once palpable tumors were established and reached 30 
mm3, mice were randomized into 2 treatment groups to receive 5 × 108 PFU 
of AdGFP (n = 8) or AdUV (n = 7) suspended in 50 µL PBS every 3 days for a 
total of 4 treatments (2 × 109 PFU) from days 6 to 15. Tumor volumes were 
determined by externally measuring these tumors in 2 dimensions with a 
caliper and calculated based upon the following equation, V = (L × W2)/2, 
where L is length and W is the width of the tumor as described previously [34, 
35]. Eight mice were treated with AdGFP and 7 mice were treated with AdUV. 
Animal experiments were performed according to the institutional guidelines 
approved by the University of Louisville Institutional Animal Care and Use 








Tumors were harvested 7 days following the fourth treatment and 
embedded in optimal cutting compound (OTC; Sakura Finetek, Torrance, CA, 
USA), and stored at -20 °C. Briefly, slides were air-dried and fixed in ice-cold 
methanol at 4 °C for 20 min. The endogenous tissue peroxidase activity was 
blocked by incubation in a 0.3% hydrogen peroxide 3% methanol solution for 
30 min according to the Vectastain ABC protocol (Vector Laboratories, 
Burlingame, CA, USA). These tissues were then blocked in SuperBlock 
(Pierce Biotechnology, Rockford, IL, USA) for 45 min at RT. Sections were 
incubated with the goat-anti-hexon polyclonal antibody (Millipore, Billerica, 
MA, USA), diluted 1:800, overnight at 4 °C. These signals were amplified by a 
biotinylated anti-goat IgG diluted 1:200 in conjunction with Vectastain avidin-
biotin complex method kit (Vector Laboratories, Burlingame, CA, USA). 
Visualization was achieved using 3,3-diaminobenzidine-tetrahydrochloride 
(DAB) for 5 min at RT; DAB staining was terminated using water (ImmPACT 
DAB peroxidase substrate; Vector Laboratories, Burlingame, CA, USA). All 
antibodies were applied and diluted in SuperBlock. Slides were washed 3 
times with PBS following the application of SuperBlock, primary antibody, 
secondary antibody and the ABC reagent. Biotinylated secondary antibody 
and ABC reagents were both applied to slides for 1 h at RT. Slides were 





























All experiments were repeated at least 3 times. Quantification of results 
were reported as the mean of 3 independent experiments plus or minus (±) 
the SD. Statistical significance was set at p-value less than 0.05. Statistical 
significance was assessed using two-way analysis of variance (ANOVA) test 
and the log-rank sum test. Multiple comparisons were corrected for by 
Bonferroni’s method. Therefore, all p-values reported from two-way ANOVA 
were adjusted using this approach. Multiple comparisons were not made for 
the log-rank sum test, therefore this p-value was not adjusted. All statistical 












3.3 – Results 
AdUV with Wild-type E1 and Mutated E3 
As described in Chapter II, AdUV was isolated following the repeated 
UV irradiation of dl309 (Ad5) which is an E1 wild-type, E3-deleted Ad [95, 
108]. The irradiated viral progeny were then subsequently selected within 
cancer cells to isolate AdUV [82]. In order to determine the mutations that 
may be responsible for the improved cancer therapeutic efficacy of AdUV, 
viral DNA was purified and sequenced as described in the methods. The E1 
and E3 sequences of AdUV were shown to match the Ad5 genome, validating 
Ad5 as the parental strain of AdUV. Twenty-five AdUV mutations with a low 
error rate of sequencing (≤15%) are listed in Table 1 (GENEID# 
AC_000008.1). Thirteen of these 25 mutations were either located within 
introns or did not alter the coded amino acid sequences of their respective 
genes. Therefore, this chapter will focus upon those 12 mutations which were 
shown to alter their respective coded amino acid sequences in the AdUV 









Reprinted with permission: Wechman et al., Viruses, 2016 
Figure 8. DNA mutations contained in AdUV. Map of the 12 
mutations in the AdUV genome which altered their respective 
encoded amino acids. Ads: adenoviruses; pTP: precursor terminal 





Site Gene Mutation aa changed? Non-conservative mutation? 
4952 IVa2 G to C T to S No, T and S are both polar uncharged aa 
8783 pTP G to A R to L Yes, R is basic (+) and L is hydrophobic 
11284 52K T to C Y to H Yes, Y is hydrophobic and H is a positivity charged aa 
12728 Intron SN deletion No No 
15829 pIII 
SN deletion,  
non-sense mutation 
G to A and lost 13 aa: IVSPRVLSSRTF Yes, lost 13 aa 
16588 pV G to A No No 
17387 pV G to C G to R Yes, G is hydrophobic and R is basic (+) 
18755 pVI SN deletion No, targeted only the last codon.  
Did not remove the codon stop 
No 
19483 Hexon T to A No No 
19513 Hexon T to A No No 
19657–8 Hexon DN substitution, GA to AG AT to AA Yes, T is polar uncharged and A is hydrophobic 
20378 Hexon T to C L to V No, both L and V are hydrophobic 
21163 Hexon C to T No No 





25995 100K A to T No No 
26561 Intron G to A No No 
26727–32 33K Six-nucleotide deletion Lost 2 aa A and A Yes, lost 2 aa 
27161 Intron C to T No No 
27314 pVIII C to A No No  
27339 pVIII T to C No No 
27650–1 pVIII DN substitution TC to CT RP to RS Yes, P is cyclic and S is polar uncharged 
28120 Intron T to C No No 
28596–601 E3 CR1-α0 Six-nucleotide deletion Lost 2 aa I and G Yes, lost 2 aa 
29750 E3A 10.5kD T to G M to R Yes, M is hydrophobic and R is basic (+) 
35776 Intron A to C No No 
 
Reprinted with permission: Wechman et al., Viruses, 2016 
Table 1. Table of AdUV mutations, their location, and changes in amino acid sequences. Conservative mutations 
are defined as changes to the encoded amino acids which have led to similar biochemical properties. We were 
interested in those non-conservative mutations in which DNA mutations altered the biochemical properties (charge, 
hydrophobicity and size) of these coded amino acids. Within the table, blue rows indicate mutations to DNA binding and 
packaging genes, green indicate mutations to Ad structural genes. White rows are indicative of mutations which were 
either conserved or occurred in genes which do not have functions related to Ad structure or DNA binding. These 
mutations were shown to have a low DNA sequencing error. The total Ad genome is 36 kilobases (kb). aa: amino acid; 




Mutations That Affect Ad Packaging 
There are several mutations in genes associated with virus packaging 
(Figure 8 and Table 1, highlighted in blue). Mutation at position 4952 changed 
the encoded threonine amino acid to a serine in the IVa2 gene, which is 
associated with virus DNA packaging and the transcriptional activation of the 
major late Ad promoter [109, 110]. AdUV was previously shown to rapidly 
transition from early to late gene expression [82]. While both threonine and 
serine serve very similar biochemical functions, the pivotal role of IVa2 to 
package the Ad genome indicates the potential relevance of this mutation. Since 
threonine and serine are both polar uncharged amino acids with very similar 
structures, this mutation is conservative. It is possible however that this mutation 
may have altered the tertiary or quaternary structure of IVa2 by replacing 
threonine with a smaller serine residue. 
The Ad terminal protein or pTP was mutated at position 8783 (Table 1 and 
in Figure 8). The pTP peptide is the precursor form of the Ad terminal protein, 
which matures following protease cleavage [111]. pTP stabilizes the origins of Ad 
DNA replication, promoting DNA synthesis by the formation of a pTP/pol dimer 
and the recruitment of the transcription factors octamer-binding protein 1 (Oct-1) 
and nuclear factor I (NFI), which bind pTP and pol, respectively [112, 113]. In 
AdUV, pTP is mutated at 8783, changing an encoded arginine with a positive 
charge at physiological pH to a hydrophobic leucine. 
A mutation at position 11284 to 52K replaced a hydrophobic tyrosine 




(Table 1 and in Figure 8). The 52K protein is a DNA binding protein [114, 115]. 
Positively charged amino acids at residues 105, 106, and 107 were essential for 
52K function [116]. Therefore, it is possible that the addition of more positively 
charged amino acids may have further enhanced these functions. 
In AdUV, the pV gene was mutated at 2 sites: 16588 (silent mutation) and 
17387. The mutation at 17387 changed the endogenous glycine amino acid to an 
arginine residue (Table 1 and in Figure 8). Glycine has a single hydrogen atom 
as a side-chain, while arginine has a large, 6-carbon nitrogenous side-chain with 
a positive charge at physiological pH. The endogenous function of pV is to form a 
shell surrounding the condensed Ad DNA during virion packaging onto the 
interior surface of the capsid during virion assembly by interaction with pVI and 
p32 [117-119]. The DNA binding functions of pV has been described as histone-
like in infected cells [120]. There are 16 known pV DNA binding sites, however, 
the DNA binding sites of pV may be altered by the interaction with pVI, pVII, or μ 
[121]. These pV peptide DNA binding sites were identified via PONDR-FIT, 
version VL-XT [122]. This mutation (17387) replaced the 281 glycine residue with 
an arginine which is not located in a known pV DNA binding site [120]. Therefore, 
the substitution of the glycine hydrogen atom side-chain for the positively 
charged arginine may have generated a novel site for pV to bind the negatively 
charged DNA sugar-phosphate backbone with greater affinity. This could 
promote viral packaging, leading to greater progeny production and increasing 




A mutation was also observed at 26727–32, which deleted 6 DNA 
nucleotides, removing 2 encoded alanine residues from 33K (Table 1 and in 
Figure 8). The 33K protein is known to play a role to assist in Ad DNA packaging, 
the transactivation of IIIa and pVI, and to serve as an alternative RNA splicing 
factor [123, 124]. Furthermore, mutant viruses with 33K deleted were shown to 
produce empty Ad capsids devoid of Ad DNA, demonstrating the requirement of 
33K expression to efficiently package Ad DNA [124]. 33K has also been shown 
to form a dimer with IVa2 to upregulate the transactivation of the major late Ad 
promoter, which helps to promote virion assembly and release [110, 125]. 
The effect of these mutations maybe to cooperate to bind and package Ad 
DNA more effectively and stimulate the rapid progression of AdUV from the early 















Mutations Affecting Other Ad Structural Proteins 
There were also several mutations in other virus structural proteins (Table 
1 and Figure 8, highlighted in green). A single nucleotide deletion in pIII at 15829 
resulted in a premature stop codon, preventing the translation of 12 amino acids 
(560–571, IVSPRVLSSRTF) into the pIII peptide (Table 1). The pIII gene has 
also been implicated for its role to package Ad DNA [126]. Once expressed, pIII 
binds with 4 other pIII macromolecules to form the penton base, which is located 
at each of the 12 vertexes of the icosahedral Ad capsid [127]. Ad serotype 2 
encoded pIII peptide (98.6% similarity to Ad5 by BLAST peptide analysis) was 
shown to be the most highly phosphorylated peptide in the Ad2 phosphatome 
with 12 total phosphorylation sites: one tyrosine, one threonine and 10 serine 
residues [128]. This truncated form of pIII expressed by AdUV may form smaller 
pIII pentamers (penton) with fewer phosphorylation sites. 
Three of 6 mutations in hexon protein changed their respective amino acid 
sequences (Table 1 and Figure 8). The mutations at 19657–8 changed a polar 
uncharged threonine into an alanine, the mutation at 20378 changed a leucine to 
a valine, and the mutation at 21630 changed the positively charged arginine to a 
smaller, polar uncharged glutamine residue (Table 1 and Figure 8). Hexon is one 
of the principal components of the Ad capsid. Each facet of the Ad capsid 
contains 12 hexon trimers with hexon pentamers positioned at each vertex of the 
icosahedral capsid [129, 130]. In vivo, hexon is highly immunogenic [131] and 
contains many hypervariable regions (HVRs) which when bound by antibodies, 




DE1 and FG1 loops between the coded 126 and 461 amino acids [132]. The 
mutations located at 20378 and 21630 are not contained within 1 of these 9 
HVRs. The 19657–8 mutation changed a threonine residue to an alanine at 
position 273; however, this mutation is also not located within any of these 9 
hexon HVRs. Therefore, these mutations should not alter the coded amino acids 
of the hexon HVRs. However, these mutations effects upon hexon 
immunogenicity in vivo are unknown at this time. 
One mutation in pVIII at 27650-1 altered the endogenous hydrophobic, 
cyclic proline amino acid to a polar, uncharged serine residue (Table 1 and 
Figure 8). Proline is the only known cyclic amino acid. Therefore proline is 
required for the formation of sharp turns or kinks during polypeptide folding [133]. 
The capsid protein pVIII is known to interact with pV on the interior of the Ad 
capsid, which together with pVI, helps to connect the Ad capsid vertexes to the 
interior of capsid and ultimately to the Ad DNA genome as virions are assembled 
[134]. The pVIII peptide contains several proline residues, from 37 to 90, which 
forms a tight α-helical structure which interacts with hexon [134]. There are also 
pVIII proline residues which contribute to the U-bend and α-helix structures [134]. 
This AdUV mutation substituted a proline for a serine at residue 160. However, 
this mutation did not occur within these crucial α-helical (37–90) and U-bend (63–
77) proline-rich domains. Therefore, this mutation may not have affected the 
polypeptide folding of pVIII as I expected. This mutation may have brought pVIII, 
pV and pVI into a more open conformation or increased the affinity of the capsid 




AdUV Displayed Greater Oncolysis and Release from A549 and Saos-2 
Cells 
As AdUV contains wild-type E1 region expression, therefore the ability of 
AdUV to lyse cancerous and non-cancerous cells was determined. MRC5 non-
cancerous lung fibroblasts, HBEC non-cancerous lung epithelial cells, and A549 
lung cancer cells were treated with AdUV, the non-selective Ad5, and the cancer 
selective (E1b-deleted) Adhz60 at an MOI of 10. Cell viabilities were determined 
via crystal violet staining after 72 h. Ad5 was shown to lyse MRC5 and HBEC 
non-cancerous lung cell lines more effectively than Adhz60 (p-value < 0.001) and 
AdUV (p-value < 0.001; Figure 9). While AdUV lysed significantly fewer HBEC 
cells than Ad5, AdUV may lyse normal lung tissue in vivo. It seems unlikely as 
that AdUV would lyse a significant number of lung cells, as Ad5-based oncolytic 
Ads have not been shown to induce pulmonary toxicity clinically. AdUV, like Ad5, 
lysed A549 lung cancer cells more effectively than Adhz60 (p-value < 0.01; 
Figure 9). Therefore, AdUV kills lung cancer cells efficiently, indicating that these 
AdUV mutations may have enhanced its oncolytic potential. 
The effect of AdUV upon A549 and Saos-2 cancer cell viability was 
determined by crystal violet staining following treatment with the indicated Ads for 
5 days. A549 cells support greater Ad replication relative to Saos-2 cells [31]. 
A549 cells displayed the greatest differences in cell viability at an MOI of 1; these 
viabilities were 91%, 40%, 67%, and 10% for AdGFP, Ad5, Adhz60, and AdUV, 
respectively (Figure 10A). Saos-2 cells displayed the greatest differences in cell 




Ad5, Adhz60, and AdUV, respectively (Figure 10B). These data indicated that 
AdUV displayed enhanced lysis of both A549 and Soas-2 cells. The enhanced 
oncolytic effects of AdUV in Soas-2 cells, the cell line used to select AdUV, 



















Reprinted with permission: Wechman et al., Viruses, 2016 
Figure 9. AdUV displays similar cancer selectivity to Adhz60 in A549 
lung cancer cells relative to HBEC and MRC5 non-cancerous lung 
cells in vitro. A549 lung adenocarcinoma, MCR5 non-cancerous lung 
fibroblast and HBEC non-cancerous lung epithelial cells were infected 
with the indicated Ads at a multiplicity of infection (MOI) of 10 for 3 days. 
They were then fixed with formaldehyde and stained using crystal violet. 
These results were then quantified and expressed as the percentage cell 
viability. Data were then analyzed using two-way ANOVA with multiple 








Reprinted with permission: Wechman et al., Viruses, 2016 
Figure 10. AdUV displays greater oncolysis than Ad5 and Adhz60 in 
A549 and Saos-2 cancer cells. (A) A549 and (B) Saos-2 cells were 
infected with the indicated viruses and MOIs for 5 days prior to crystal 







To study AdUV release from cancer cells, A549 and Saos-2 cancer cells 
were infected with AdUV, Ad5, or Adhz60 at an MOI of 1. Six h after infection, 
these cells were washed with fresh culture media prior to collecting 25 µL of the 
cell culture media every 24 h for 5 days. These samples were then titered on 
HEK293 cells using the TCID50 approach. The titer of each Ad was shown to 
increase with time in both A549 and Saos-2 cancer cell lines (Figure 11A,B). 
AdUV displayed higher viral titers than Ad5 and Adhz60 at each time point in 
A549 and Saos-2 cells. At 72 h, Ad media titers were 5.9 × 108, 8.73 × 107, 2.18 
× 107 for AdUV, Ad5, and Adhz60 treatments respectively (Figure 11A). At 72 h, 
the titer of AdUV in the cell culture media was 10 fold greater than Ad5 and 30 
fold greater than Adhz60. AdUV also displayed higher titers in Saos-2 cells than 
Ad5 and Adhz60. At 72 h, AdUV titer was 2.28 × 106, while titers of Ad5 and 
Adhz60 titers were 5.60 × 105 and 2.19 × 105, respectively (Figure 11B). These 
data indicate that AdUV is released from both A549 and Soas-2 cancer cells 













Reprinted with permission: Wechman et al., Viruses, 2016 
Figure 11. AdUV displays greater release than Ad5 and Adhz60 in 
A549 and Saos-2 cancer cells. (A) A549 and (B) Saos-2 cells were 
infected with the indicated Ads at an MOI of 1. Day 0 media samples 
were collected 6 h post-infection; after these samples were collected, 
cells were then washed with cell culture media to remove non-
internalized Ad particles. Media samples were then collected every 24 h 
for 5 days. These samples were then titered on HEK293 cells using the 





AdUV Inhibits Tumor Growth in Nude Mice 
The efficacy and safety of AdUV was further tested in vivo using an A549 
subcutaneous athymic nude mouse (NCr-nu/nu) xenograft model. Once tumors 
grew to 30 mm3, mice were randomized and treated via intratumoral (IT) injection 
with 5 × 108 plaque forming units (PFU) of AdUV or the negative control AdGFP 
every 3 days for a total of 4 treatments (Figure 12A). The length and width of 
each tumor were measured using a caliper every 3 days. Mice treated with AdUV 
exhibited significantly suppressed tumor growth. AdUV with 94% reduction in 
mean tumor volume compared with mice treated with the control AdGFP vector 
at day 51 (p-value < 0.001, Figure 12A). Furthermore, all AdUV treated mice (n = 
7) survived until day 125 (p-value = 0.0005) while only 2 AdGFP treated mice (n 
= 8) survived to that time point (Figure 12B). Representative photographs were 
taken of mice treated with AdGFP or AdUV at day 51 to display the marked 
qualitative differences between the 2 treatment groups (Figure 12C). 
Furthermore, weight loss or lethargy was not observed following AdUV treatment. 
In addition, AdUV was shown to express the viral late protein, hexon, in A549 
xenograft tumor sections 7 days after the final viral injection, which was not 
detected in tumors treated with AdGFP (Figure 12D). These results indicate that 








Reprinted with permission: Wechman et al., Viruses, 2016 
Figure 12. The effect of AdUV upon A549 xenograft tumor growth 
and nude mice survival. Xenograft tumors were formed following the 
subcutaneous (SC) injection of 5 × 106 A549 cells into the right flank of 
athymic nude mice (NCr-nu/nu). (A) Tumors were then intratumorally (IT) 
injected with AdGFP or AdUV 4 times from day 6 until day 15 for a total 
dose of 2 × 109 PFU; (B) Mice were sacrificed once tumors were greater 
than 1000 mm3 in size. Data were expressed as the percent (%) of death 
among each treatment groups across time; (C) Representative mice 
treated with AdGFP and AdUV were photographed at day 51. Boxes 




representative mice per treatment group; (D) Immunohistochemistry for 
hexon expression in A549 tumors harvested 7 days after the final 
injection. Slides were photographed at 200× and 400× total 
magnifications respectively. Differences in tumor growth were assessed 
by two-way ANOVA. Adjusted p-values were reported for multiple 
comparisons via Bonferroni’s method at each time-point. Differences in 
murine survival were determined using the Kaplan-Meier log-rank sum 
test. * indicates p-value < 0.05, † indicates p-value < 0.01, ‡ indicates p-














3.4 – Discussion 
The goal of this study was to investigate which Ad genes may affect Ad 
oncolytic efficacy, and therefore, may be modified and combined with other 
approaches for the development of future oncolytic Ads. The Ad early genes in 
AdUV, E1a and E1b, E2, and E4, remained unchanged however, some critical 
Ad late genes were mutated and are worthy of additional study. These AdUV 
mutations likely enhanced Ad-mediated cancer cell lysis and cancer selectivity. 
Twelve of these mutations in the AdUV genome of interest were shown to alter 
the encoded amino acids, 5 of these mutations occurred within Ad capsid 
structural genes (pIII, Hexon, pVIII). Another 5 mutations occurred within genes 
encoding DNA binding or DNA packaging proteins (IVa2, pTP, 52K, pV, 33K). 
Two mutations, E3A 10.5kD and E3 Cr1-α0, were not discussed in detail, which 
may have affected the receptor internalization and degradation (RID) pathways 
and immune cell–cell interactions, respectively.  
The absence of mutations in the Ad early genes, E1 and E4, was 
surprising as these genes have important roles in an array of virus–host 
interactions. By far, the development of cancer selective Ads has focused upon 
the modification of the Ad early genes by the introduction of deletions to E1b-19K 
and E1b-55K or the regulation of E1a expression using cancer-selective 
promoters [34, 135]. However, these data indicate that the late gene-encoded 
structural proteins may also influence Ad replication, release, and oncolysis 




Ad5 at 8350 was associated with large plaque formation in cancer cells due to 
the truncation of 21 amino acids in a gene called i-leader [60]. 
In this chapter, mutations in 6 different Ad proteins with known roles to 
package viral DNA during virion maturation are described. These Ad capsid 
proteins include IVa2, pTP, 33K, pV, 52K and pVIII. In particular, pV, IVa2, pVI 
and pVIII interact with and anchor Ad DNA onto the capsid [137]. The mutations 
in pVIII, pV and IVa2 are all on the interior of the Ad capsid and have been 
shown to cooperate to facilitate the packaging of DNA into the Ad capsid to 
produce mature virions. The mutations occurring within pV, and its interaction 
partners IVa2 and pVIII, indicate the importance of these proteins for DNA 
packaging which could support the rapid release of Ads. 
AdUV was shown to rapidly transition from early to late phase gene 
expression as indicated in figure 4A [82]. IVa2 and 33K form a complex to 
stimulate the transcription of the major late Ad promoter [110, 125]. It is possible 
these IVa2 and 33K mutations found in AdUV may have increased the formation 
of this complex to induce early to late phase transition during Ad replication. 
Furthermore, there exists indirect evidence that IVa2 and 33K can also form a 
complex with DNA-binding protein (DBP) on one of the Ad capsid vertexes, 
facilitating Ad DNA packaging [110]. These mutations acting together may be 
associated with rapid AdUV virus assembly and release. 
These results also indicate that AdUV can be safely used in animals and 
suppress tumor growth. AdUV is an E1b wild-type Ad. In early oncolytic studies 




However, wild-type Ads are no longer used in clinical studies because of safety 
concerns and their limited cancer therapeutic efficacy. For this reason, AdUV, 
which is based on wild-type Ad5, is unlikely used in future clinical studies. 
Therefore, the goal of this limited animal study to investigate whether these novel 
AdUV mutations were toxic to animals. To study these mutations further, each 
mutation should be individually introduced into a well-characterized Ad vector 
background to understand their impact upon Ad replication and oncolytic therapy.  
The expression of E1b by AdUV also likely enhanced its oncolytic 
potential. Several E1b wild-type oncolytic vectors have been described in the 
literature with increased cancer therapeutic efficacy containing other modes of 
cancer selectivity such as cancer selective promoters, or partial E1a deletions 
[81, 139]. Even though E1b expression is not essential for Ad replication in 
cancer cells [31], E1b may enhance the efficiency of Ad replication in cancer 
cells, likely via cyclin E induction [31]. Recently published data, shown in chapter 
II, indicates that E1b upregulates autophagy; however, the mechanism of 
autophagy induction by E1b remains unknown [82]. Autophagy is known to 
degrade intracellular components, organelles and long-lived proteins [140-142]. It 
appears that E1b may drive Ad-mediated autophagy induction to promote virus 
replication by generating nutrient to build virus particles [55, 66]. Therefore, the 
oncolytic effects and replication of AdUV was likely enhanced by E1b. 
These findings taken together provide additional insight into the 
construction of oncolytic Ads. It appears that E1b expression and mutations in 




augment Ad release and spread within tumor tissue, leading to enhanced 
oncolytic therapy efficacy. One of the limitations of this study is that the specific 
effects of these mutations upon oncolytic replication are unknown at this time. It 
is also possible that several of these mutations may cooperate to enhance 



















THE ROLE OF JNK PHOSPHORYLATION AS A MOLECULAR TARGET TO 
ENHANCE ADENOVIRUS REPLICATION, ONCOLYSIS AND CANCER 
THERAPEUTIC EFFICACY 
4.1 – Introduction 
 Oncolytic Ads represent an emerging class of lung cancer therapeutics 
with clear cancer selectivity in vitro [33, 55, 90]. E1b-deleted Ads selectively lyse 
cancer cells very efficiently in vitro; however, these viruses were ineffective 
during clinical trials [19, 53, 143, 144].  
 To overcome the limitations of Ad therapy, a more complete 
understanding of Ad-mediated cancer cell lysis or oncolysis is necessary. Among 
the programmed cell death pathways (apoptosis, necrosis, and autophagy), 
autophagy inducers have been reported to support Ad replication and oncolysis 
[66, 77]. Therefore, autophagy is of significant interest as a potential driver of Ad 
oncolysis. Many viruses interact with autophagy signaling during infection, 
however autophagy can inhibit or promote virus replication. For example, 
autophagy inhibits HIV-1 [145], HSV [146] and influenza A infection [147]. 
However, Ads induce autophagy to promote their own replication and to lyse 
cancer cells [66], indicating that Ads induce autophagy to produce their anti-
tumoral effects [77]. Furthermore, the autophagy inhibitors 3MA and Baf-A1 
inhibited Ad replication and protect cancer cells from Ad oncolysis [66, 78]. 




the autophagy markers LC3-II and p62 [34, 66]. Therefore, E1b may play a role 
as an autophagy inducer. 
 The field of oncolytic adenovirology has not emphasized the 
investigation of autophagy and its induction by E1b. Therefore, the effect of 
various autophagy signaling pathways upon the replication or oncolytic effects of 
E1b-deleted Ads is unknown. Autophagy induction occurs predominantly via 2 
mechanisms: 1) glucose starvation 2) phosphoinositide 3-kinase (PI3K) and MAP 
Kinase (MAPK) signal transduction. Autophagy induced via glucose starvation is 
driven by the energy-sensor AMP-activated protein kinase (AMPK) which 
promotes autophagy-mediated cellular catabolism [148, 149]. AMPK 
phosphorylates Ulk1 at serine 317 and 777, activating Ulk1 leading to 
autophagy induction [148]. mTOR disrupted AMPK coordinated Ulk1 
phosphorylation and phosphorylates Ulk1 at serine 757 to inhibit autophagy 
[74]. Furthermore, rapamycin treatment (an mTOR inhibitor) enhanced E1b-
deleted Ad replication and oncolysis. Studies have indicated that mTOR 
activation is dependent upon the E4-ORF4 protein phosphatase 2A-binding 
domain and that mTOR supports the S-phase entry of G0-phase primary cells 
[150]. In this way, E4-ORF4 is thought to enhance Ad replication.  
 Interestingly, Ads do not appear to induce autophagy via the cell 
starvation AMPK pathway. Preliminary studies indicated that E1b wild-type 
Ads induce autophagy via c-JUN n-terminal kinase (JNK) phosphorylation, which 
occurs independently of the AMPK/mTOR-induced cell starvation autophagy 




of BCL-2, activating BECLIN-1 [36, 81, 152]. JNK and the map kinase (MAPK) 
pathway may play a crucial role to upregulate ATG5 expression [153]. The first 
report, to my knowledge, to demonstrate that Ads induced JNK phosphorylation 
via E1b was published by See and Shi in 1998; however, this report did not 
indicate if Ad induced p-JNK to enhance Ad replication or oncolysis [80]. Klein et 
al. reported that JNK expression was essential for the E1b wild-type Ad, 
Δ24RGD, to induce autophagy in vitro and in vivo [81]. The goal of this chapter 
was to characterize the induction of p-JNK by E1b-deleted Ads and the role of p-
JNK to stimulate Ad replication and cancer cell oncolysis.  
 Ads have been shown to manipulate both apoptosis and autophagy via 
the expression of E1a, E1b-19K, and E1b-55K to lyse cancer cells in a highly-
coordinated manner. E1A is known to stabilize TP53 inducing apoptosis [96], 
while E1b-19K and E1b-55K counter act these effects by antagonizing BAK/BAX 
and TP53 respectively. Simultaneously, E1b-19K and E1b-55K also stimulate 
MKK7-mediated JNK phosphorylation to induce autophagy [80, 154]. Therefore, 
E1b expression appears to drive Ad oncolysis towards an autophagy-mediated 
mechanism; however, the effects of E1a upon JNK phosphorylation remains 
unknown. Interestingly, E1b-deletions are not sufficient to completely abolish 
JNK phosphorylation by oncolytic Ads, implicating the role of E1a as an inducer 
of both apoptosis and JNK phosphorylation.  
 In this chapter, the ability of oncolytic Ads to induce JNK phosphorylation 
via E1a or E1b was assessed using Ads which selectively over express E1a and 




both E1b and E1a were crucial for efficient JNK phosphorylation in A549 lung 
cancer cells. To determine in p-JNK inducers enhanced Ad replication and 
oncolysis, known chemical p-JNK inducers were screened to determine which 
drug was the most effect p-JNK inducer in A549 cells; this drug (etoposide) was 
then used in combination with the previously developed oncolytic Ad AdUV [82, 
136]. These data indicated that etoposide enhanced AdUV oncolysis; however, 
etoposide was not shown to enhance AdUV replication using these conditions. It 
is expected that etoposide induced p-JNK production via a non-specific 
mechanism of action. Therefore, the selective effects of JNK activation upon 
oncolytic Ad replication and oncolysis was assessed using siRNA, targeting both 
JNK1 and JNK2 mRNAs sequences [155, 156]. The suppression of JNK1/2 was 
shown to protect cancer cells from Ad-mediated A549 cell lysis. Ad replication 
was also significantly repressed in JNK1/2 siRNA-transfected cells infected by 
the E1b-19K wild-type Ads Ad5 and Adhz63, but not the E1b19K-deleted Ad 
Adhz60. These studies have demonstrated for the first time that p-JNK is not only 
essential for Ad oncolysis, but also for Ad replication. These data suggest that 
JNK is an intriguing molecular target to enhance the therapeutic effects of 








4.2 – Materials and Methods 
Cell Lines and Culture Conditions 
HEK293 (ATCC no. CRL-1573) human embryonic kidney and A549 
(ATCC no. CCL-185) human lung carcinoma cells were purchased from the 
ATCC (ATCC, Rockville, MD, USA). A549 and HEK293 cells were maintained in 
DMEM supplemented with 10% fetal bovine serum, L-glutamine, and 
penicillin/streptomycin (100 U/mL). All other cell culture reagents were obtained 
from VWR (VWR, Radnor, PA, USA). All cells were cultured and maintained in 
















Ad5 dl309 is E1 wild-type E1 [95] and was used as a non-selective Ad 
control in these studies. Adhz63 is an E1b55K-deleted Ad similar to dl1520 and 
H101 and was used as a cancer selective control [96]. Adhz69 is an E1b55K-
deleted Ad that over-expresses E1A via the CMV promoter [157]. Adhz60 is an 
E1b55K, 19K-deleted vector used as a cancer selective control and E1b19K-
deleted Ad control for these studies [96]. AdUV is an E1b wild-type mutant 
oncolytic Ad based upon Ad5 as described previously [82, 136]. AdGFP is E1 
(E1a and E1b) deleted, with green fluorescent protein (GFP) expression driven 
by the CMV promoter [55]. AdGFP, as a negative control, does not replicate nor 
induce CPE [34, 35]. All Ads used in this study are based upon Ad5 backbone 













Plasmid amplification and transfection 
To chemically transform a plasmid into chemically competent bacteria, the 
bacteria were mixed with between 200 ng and 1 μgs of plasmid DNA on ice for 
30 min. The mixture was then transferred into a 42 °C water bath for 30 s. After 
the heat shock, the bacteria/plasmid mixture was returned to the ice for 2 min. 
250 μL of SOC media (Corning Cellgro, Tewksbury, MA) was then added to the 
mixture and placed at 37 °C for 1 h. This mixture was plated on LB agar plates 
containing 100 µg/mL of ampicillin. The plates were incubated at 37 °C overnight. 
Colonies were selected the next day and grown in LB broth media, again 
supplemented with the proper antibiotic at the correct final concentrations listed 
above, and once again incubated overnight at 37 °C in a shaker set at 300 RPM. 
After the colonies were expanded and grown in LB media, these cultures were 
then processed to isolate DNA plasmids using Qiagen Mini, or Maxi-scale kits 
(Qiagen, Hilden, Germany). Mini-scale cultures utilized 3-5 mL of 100 µg/mL 
ampicillin containing Luria-Bertani (LB) broth, while Maxi-scale cultures utilized 
250-500 mL of 100 µg/mL ampicillin LB broth. The entire culture was then 
pelleted using an AvantiJ-26XPI centrifuge (Beckman Coulter, Brea, CA, USA) 
spun at 8000 xg for 3 (Mini-scale) to 15 (Maxi-scale) min respectively. Following 
centrifugation, the media were decanted and the entire pellet was resuspended 
in RNAseA containing P1 buffer provided by the kit. The plasmid extraction and 
purification steps from this point forward were carried out in accordance with the 




Two plasmids were used during the completion of these studies. The 
CMV-E1b19K plasmid was a generous gift from Dr. Eileen White at Rutgers 
University [158]. The pCycE-GFP plasmid was constructed by Dr. Heshan Zhou 
at the University and Louisville and was used as a negative control; pCycE-GFP 
was also used to determine plasmid transfection efficiency [31]. 2 × 105 A549 
cells were seeded onto 6-well plates overnight for transfection. Cells were 60-
70% confluent the next day; however, small gaps were present between those 
cells, ensuring maximal transfection efficiency. These cells were then transfected 
with 2 µg of plasmid DNA using Jetprime according to the manufacturer’s 
protocol for DNA transfection. The media of these transfected cells were 
changed after 4 h. Using these conditions, a transfection efficiency of at least 













Drug preparation  
Etoposide, cytrabine, cycloheximide, and paclitaxel were all purchased 
from sigma (Sigma-Aldrich, St. Louis, MO, USA) and diluted into 100% DMSO at 
a stock concentration of 10 mM. These stock solutions were then diluted in 
serum-containing media to 1 mM for use at the indicated micromolar (µM) 
concentrations indicated. Drug treatments were applied to the cells in culture 


















To ascertain the role of JNK expression upon Ad replication and oncolysis, 
siRNA transfection was utilized. Both JNK1 and JNK2 are phosphorylated by 
Ad5, therefore the suppression of both JNK1 and JNK2 was necessary [81]. The 
JNK1/2-siRNA utilized in this study: JNK1/2 5’- AAAGAAUGUCCUACCUUCU-3’ 
was initially described by Dr. Li in 2004 and targets JNK1 and JNK2 at the mRNA 
positions 377 and 425 respectively [155]. JNK1/2-siRNA was ordered by email 
using the sequence from Dr. Li and its duplex complement from Thermo Fisher 
Scientific (Thermo Fisher Scientific, Waltham, MA, USA). The optimal siRNA 
concentration to suppress JNK1 and JNK2 was assessed by transfecting A549 
cells with 10 to 400 nM of JNK1/2-siRNA. These transfected cells were then 
lysed and studied by Western blot analysis to determine whether efficient JNK1 
and JNK2 protein production was suppressed. 120 µg of these protein isolates 
were electrophoresed on 10% SDS-PAGE gels and JNK1 and JNK2 production 
was probed using JNK1 (1:100) and JNK2 (1:200) selective antibodies from 











Virus Titration and Release 
A549 cells were seeded onto 12-well plates at a density of 4 × 104 cells 
per well and allowed to adhere overnight. Cells were then treated as indicated 
and harvested with a cell scraper. These samples were then subjected to 3 
freeze-thaw cycles to release all the Ads into solution for the determination of 
total Ad titer by the median tissue culture infective dose (TCID50) method as 

















Western Blot Analysis 
A549 cells were seeded onto 60 mm dishes overnight at a density of 3 × 
105 cells per dish. Cells were collected and centrifuged at 1500 RPM (453 RCF) 
at 4 °C for 5 min using an Eppendorf 15 amp 5810R refrigerated centrifuge 
equipped with a A-4-62 rotor (Eppendorf, Hamburg, Germany). The cell pellets 
were then washed with PBS prior to lysis with RIPA buffer containing 50 mM 
Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS 
with PI containing 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF), pepstatin 
A, trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane (E-64), bestatin, 
leupeptin, and aprotinin (10 mL / 1 × 106 cells; Sigma, St. Louis, MO, USA). The 
cell lysates were then incubated on ice in PI containing RIPA buffer for 30 min 
and homogenized every 10 min using a vortex-genie 2 (Scientific Industries, 
Bohemia, NY, USA). These lysates were then centrifuged at 14,500 RPM 
(196,000 RCF) at 4 °C for 10 min using a micromax RF microcentrifuge equipped 
with an IEC 851 rotor to pellet cell debris formed during lysate preparation 
(Thermo Fisher Scientific, Waltham, MA, USA). The pellet was discarded and the 
supernatant was stored at -80 °C for further experimentation. Protein 
concentrations were determined using the Pierce BCA protein assay kit 
according to the manufacturer’s instructions (Thermo Fisher Scientific, Waltham, 
MA, USA). Equal amounts of cellular protein were resolved by electrophoresis 
through 8% (E1A), 10% (JNK, p-JNK, JNK1, JNK2, E1b-19K, actin) or 12% 
(LC3-I and LC3-II) SDS-polyacrylamide gels prior to transfer to methanol 




dry transfer apparatus (BIO-RAD, Hercules, CA, USA). Membranes were then 
blocked using 5% nonfat milk prepared in TBST for 1 h at room temperature. To 
detect protein expression, membranes were incubated with the following primary 
antibodies: rabbit-anti-human-LC3 (1:3000; Novus Biologicals, Littleton, CO, 
USA), rabbit-anti-human-actin (1:2000; Sigma, St. Louis, MO, USA), rabbit-anti-
human p-JNK (1:1000; Cell Signaling, Danvers, MA, USA), rabbit-anti-human-
JNK (1:1000; Cell signaling, Danvers, MA, USA), mouse-anti-human-JNK1 
(1:100; Santa Cruz, Dallas, TX, USA), mouse-anti-human JNK2 (1:200; Santa 
Cruz, Dallas, TX), mouse-anti-Adenovirus2-E1b19K (1:150; Calbiochem, San 
Diego, CA, USA) or mouse-anti-adenovirus-E1A (1:1000; BD Pharmagen, San 
Jose, CA, USA) at 4 °C overnight on a lab-line thermal rocker (Thermo Fisher 
Scientific, Waltham, MA, USA). The mouse-anti-Adenovirus2-E1b19K antibody is 
cross-reactive with Ad serotype 5 (Ad5). Primary antibody binding was detected 
by the incubation with the horseradish peroxidase (HRP) linked anti-mouse or 
anti-rabbit immunoglobulin (Ig) diluted 1:5000 for 1 h at room temperature 
(Amersham, Piscataway, NJ, USA). All antibodies were diluted in TBST. 
Enhanced chemiluminescence (ECL) reagents were used to detect HRP-linked 
secondary antibody binding according to the manufacturer’s instructions 









A549 cells were seeded at a density of 2 × 104 cells per well onto 24-well 
plates and allowed to adhere overnight. Cytotoxicity was assessed by crystal 
violet staining at the time-points indicated [97]. Suspended cells were aspirated, 
and the adherent cells were then fixed via incubation with 3.7% formaldehyde for 
25 min at room temperature (RT). Excess formaldehyde was washed away using 
PBS. Cells were then stained using 1% crystal violet for 30 min at RT. Excess 
crystal violet was washed away with water. These crystal violet stained wells 
were then scanned using an HP Scanjet 4070 scanner (HP, Palo Alto, CA, USA). 
The remaining crystal violet was then solubilized with a 2% SDS solution, and the 
sample ODs were measured at 590 nm using a Synergy HT Multi-Mode 
Microplate Reader (Bio-Tek, Winooski, VT, USA). These OD values were then 
normalized to mock-treated cells, converting each sample OD into the percent 
(%) cell viability by the formula, cell viability % = (OD of treated cells/OD of mock-












All experiments were repeated at least 3 times. Quantification of results 
was reported as means of 3 independent experiments plus or minus (±) the SD. 
Statistical significance was set at p-value less than 0.05. Statistical significance 
was assessed using the two-way ANOVA test for the EC50 combination ratio 
study (Figure 18A) corrected for multiple comparisons via Bonferroni’s test. All 
other statistical tests were conducted using one-way ANOVA with Tukey’s post-
test for multiple comparisons. However, the statistical analysis of the p-JNK fold 
changes induced by Ad5 treatment across time (Figure 13B,C) was conducted 
using one-way ANOVA with Dunnett’s post-test. All statistical tests were 














4.3 – Results 
Adenovirus serotype 5 induces p-JNK expression in A549 cells 
To observe the effect of Ad infection upon JNK phosphorylation, A549 
lung cancer cells were infected with the wild-type serotype 5 Ad (Ad5) at an MOI 
of 10. Infected or non-infected (Mock) cells were then observed for CPE and for 
the production of p-JNK via Western blot analysis from 18 to 72 h post-infection. 
These data indicated that E1b wild-type Ads, such as Ad5, led to a time-
dependent induction of CPE and p-JNK; induced p-JNK production was began at 
18 h (4.1 fold) reaching the greatest p-JNK production at 72 h (18.4 fold) post-
infection (Figure 13A-C). The highest levels of p-JNK production (48, and 72 h) 
was associated with changes in A549 cell morphology consistent with CPE 
(Figure 13A,C). To quantify the effects of Ad5 upon CPE and oncolysis, A549 
cells were stained with crystal violet at the time-points indicated. These data 
were expressed as a percentage of Ad5 treated cell viability relative to mock cells 
at each time-point (Figure 13C). By plotting these fold changes in p-JNK and 
LC3-II production overtime, the effects of Ad5 upon the induction of p-JNK (18 h) 
occurred first, prior to the induction of LC3-II (36 h), A549 oncolysis, and CPE 
induction by Ad5 at 48 and 72 h (Figure 13C). These data indicate that the E1b 
wild-type Ad Ad5 induced JNK phosphorylation during A549 cell oncolysis. This 
was especially evident during the late phases of infection at 48 and 72 h post-






Figure 13. The effect of Ad5 upon JNK phosphorylation. A549 cells were 
mock treated or infected with Ad5 at an MOI of 10 and then observed from 0 to 
72 h post-infection. (A) CPE induced by Mock or Ad5 treatment in A549 cells was 
observed at the indicated time-points. Pictures were taken using an inverted 
microscope at 200x total magnification. 600 µm scale bar is located in the top 
right corner. (B) A549 cell lysates were treated and harvested at the time-points 
indicated and observed for protein production via Western blot analysis. (C) 
Quantification of these Western blot data normalized to actin protein expression. 
Cell viability was determined by crystal violet staining and plotted on the 




minus the standard deviation. Statistical analysis was performed using one-way 
ANOVA by Dunnett’s test for multiple comparisons relative to the mock control (1 





















The effects of E1b upon p-JNK activation 
To determine whether E1b-deleted Ads induced JNK phosphorylation, we 
infected A549 cells with the E1b wild-type Ad5, the E1b55K-deleted Adhz63 and 
the E1b55,19K-deleted Adhz60 at a MOI of 10 and observed for p-JNK 
production by Western blot analysis. Differences in p-JNK production were first 
assessed at 36 h post-infection prior to A549 cells lysis (Figure 14A). However, 
no differences in p-JNK production were observed between E1b wild-type and 
E1b-deleted Ad treatments at any of the 3 MOIs (1, 3, and 10) tested (Figure 
14B,C). Therefore, the effects of Ad5, Adhz63 and Adhz60 upon p-JNK 
production at 48 and 72 h post-infection were assessed. These data indicated 
that p-JNK production by Ad5 (32.2 fold), Adhz63 (28.1 fold) and Adhz60 (10.9 
fold) were significantly different at 72 h post-infection (Figure 15A-C).  
Interestingly, Adhz63 was shown to induce similar p-JNK production to 
Ad5 (28.1 fold vs. 32.2 fold respectively), while Adhz63 induced similar oncolytic 
effects to Adhz60 at 72 hours (Figure 15C,D). These data indicate that E1b-19K 
expression, via Adhz63, may be critical for inducing p-JNK production. Therefore, 
a plasmid that expresses E1b-19K under control of the CMV promoter (CMV-
E1b19K) was utilized to selectively assess the role of E1b19K as a p-JNK 
inducer (Figure 15E). These data indicated that E1b-19K expression was 
sufficient to induce p-JNK production (22.7 fold) in A549 cells alone, 
demonstrating the potentially critical role of E1b-19K to activate JNK signally 











Figure 14. The effect of selective E1b-deleted Ads upon p-JNK at 36 h. A549 
cells were mock-treated or infected with Ad5, Adhz63, and Adhz60 at an MOI of 
1, 3 and 10 respectively. (A) Crystal violet staining of A549 cells treated as 
indicated at 36 h post-infection. (B) A549 cell lysates were prepared at 36 h post-
infection and observed for the production of the indicated proteins via Western 
blot analysis. (C) Quantification of these Western blot data was normalized to 
actin protein expression. Results were expressed as the average of 3 






















Figure 15. The effect of E1b-19K expression upon JNK phosphorylation. 
A549 cells were mock treated or infected with AdGFP, Ad5, Adhz63 and Adhz60 
at an MOI of 10. (A) CPE induction in mock, AdGFP, Ad5, Adhz63 and Adhz60 
treated cells. Pictures were taken using an inverted microscope at 200x total 
magnification at 48 and 72 h post-infection. 600 µm scale bar is located in the top 
right corner. (B) A549 cell lysates were observed for the production of the 




blot data normalized to actin protein expression. (D) Cell viability was determined 
by crystal violet staining and expressed as the percent cell viability relative to 
non-treated cells. (E) A549 cells were mock transfected, or were transfected with 
GFP or CMV-E1b19K expressing plasmids as indicated. These cells were then 
lysed and observed for the production of the indicated proteins. IOD is an 
abbreviation for integrated optical density. IOD’s were determined via 
densitometric analysis using Gel-pro analyzer 4.0 software. * indicates p-value < 















The effect of E1a upon p-JNK production 
 While extensive research has focused upon the role of E1b as an inhibitor 
of apoptosis, recent reports indicate that E1b is also required for JNK 
phosphorylation; however, effects of other Ad genes upon JNK phosphorylation 
is unknown [159]. E1a has been shown to induce JNK phosphorylation in murine 
3T3 fibroblasts; however, the effect of E1A upon p-JNK in cancer cells following 
oncolytic Ad infection remains unknown [159]. In this report, the total E1b-deleted 
Ad Adhz60 did not display totally ablated p-JNK production (10.9 fold), indicating 
that other Ad genes may also play a role to induce JNK phosphorylation (Figure 
15C). Furthermore, E1b-deleted Ads have been shown to depend upon efficient 
E1a expression to lyse cancer cells [29], implicating the role of E1A as a potential 
inducer of p-JNK production during cancer cell oncolysis. 
To assess the role of E1A as a p-JNK inducer, A549 cells were treated 
with Ad wild-type Ad5, the E1b55K-deleted E1a wild-type Adhz63, and the 
E1b55K-deleted CMV-E1a Adhz69. Therefore, by comparing between the 
Adhz63 and Adhz69 treatment groups, the effects of increased E1a production 
upon p-JNK is evident as both of these Ads have identical E1b55K-deleted 
backgrounds. These data indicated that selective E1a over-expression by 
Adhz69 lead to increased E1A and p-JNK production (39.9 fold) relative to Ad5 
(12.4 fold) and Adhz63 (3.8 fold) in the absence of E1b-55K expression (Figure 
16B).  
 E1A is a well-known transactivator of many Ad and host cell genes [160]. 




JNK production in A549 cells as shown in Figure 15E. Therefore, the effects of 
E1A over-expression upon E1b-19K protein production was observed to 
determine if Adhz69 induced p-JNK production was due, at least in part, to 
enhanced E1b-19K expression (Figure 16C). Ad5 and Adhz60 were used as 
E1b-19K production positive and negative controls respectively for this 
experiment. These data have shown that markedly enhanced E1A production by 
Adhz69 is not significantly increase E1b-19K production relative to Adhz63 in 
A549 cells (31.0 IOD vs. 20.1 IOD; Figure 16C). Therefore, E1a likely drives p-















Figure 16. The effect of E1a expression upon JNK phosphorylation. A549 
cells were mock-treated or infected with AdGFP, Ad5, Adhz63, and Adhz69 at an 
MOI of 10. (A) Cell viability was determined by crystal violet staining and 
expressed as the percent cell viability relative to non-treated cells at 48 h post-




and observed for the protein production of the indicated proteins via Western blot 
analysis. (C) E1b-19K protein production was determined via Western blot 
analysis. Adhz60 is E1b-19K deleted and was used as a negative control. IOD is 
an abbreviation for integrated optical density. IOD’s were determined via 



















Evaluating known p-JNK inducers as enhancers of Ad oncolysis 
Four p-JNK inducing cancer chemotherapeutics (etoposide, cytarabine, 
cycloheximide and paclitaxel) were evaluated for their p-JNK induction in A549 
cells [83-86]. First, the effective concentration 50% (EC50) of each of these 
drugs to lyse A549 cells were determined (Figure 17A). To evaluate which drugs 
induced p-JNK production most efficiently, A549 cells were treated at their 
EC50s for 24 h and then their effects upon p-JNK production were assessed via 
Western blot analysis. These data indicated that etoposide and cycloheximide 
induced p-JNK production; while cytarabine and paclitaxel did not induce p-JNK 
using these conditions (Figure 17B).  
These data led to additional studies to determine if etoposide or 
cyclohexamide enhanced Ad replication and oncolysis. Using the median-effect 
method of Chou and Talalay [161], the effect of etoposide and cyclohexamide 
upon AdUV oncolysis was determined [82, 136]. Among these two drugs, the 
oncolytic effects of AdUV was only enhanced following etoposide treatment in 
A549 cells (p-value < 0.001) using the combination ratio of 0.5 MOI and 0.7 µM 
respectively (Figure 17C). Upon further dose-escalation of this combination ratio, 
the greatest differences in AdUV oncolysis were observed between AdUV alone 
at an MOI of 1 (70%) and AdUV (1 MOI) in combination with etoposide at 1.4 µM 
(54%; Figure 18A). Using these conditions, however, etoposide was not shown to 
enhance AdUV replication (Figure 18B). These data indicated that the p-JNK 






Figure 17. The effect of etoposide upon p-JNK and Ad oncolysis. A549 cells 
were treated with etoposide, cytrabine, cycloheximide and paclitaxel to determine 
their EC50s in A549 cells. (A) EC50 values as determined using crystal violet 




EC50’s upon JNK phosphorylation was determined by Western blot analysis. (C) 
Crystal violet staining for A549 cells treated with AdUV at 0.5 MOI alone, 0.7 µM 
etoposide or in combination. Significance was assessed via one-way ANOVA 





















Figure 18. The effect of etoposide upon Ad replication and oncolysis. A549 
cells were treated with etoposide and AdUV at a constant ratio of 0.5 MOI AdUV 
to 0.7 µM etoposide, respectively. (A) Crystal violet staining of A549 cells treated 




enhanced AdUV oncolysis. Significance was assessed via two-way ANOVA with 
Bonferroni’s post-test analysis for multiple comparisons. (B) AdUV titer as 
determined by the TCID50 method. Significance was assessed via one-way 
ANOVA with Tukey’s post-test analysis for multiple comparisons. † indicates p-



















The selective effects of JNK upon Ad replication and A549 cell oncolysis 
Wild-type Ad infection has been shown to induce JNK1 and JNK2 
phosphorylation [80, 81]. Therefore, the suppression of both JNK1 and 2 using 
siRNA was necessary to elucidate effects of JNK upon Ad replication and 
oncolysis.  
First, A549 cells were either mock treated or transfected with 10 to 400 nM 
of JNK1/2-siRNA. Cells were screened for efficient JNK1/2 suppression via 
Western blot analysis with JNK1 and JNK2 selective antibodies. Using this 
approach, JNK1/2-siRNA selectively inhibited JNK1 and JNK2 expression at 200 
and 400 nM respectively; the 400 nM transfection condition was selected as this 
condition displayed the most efficient suppression of both JNK1 and 2 (Figure 
19A). JNK1/2-siRNA transfection protected A549 cells against oncolysis relative 
to scramble-siRNA transfected cells (Figure 19B). This protective effect was 
observed for Ad5, Adhz63 and Adhz60. The greatest differences, however, were 
seen in Ad5-infected cells (cell viability 29% vs. 61% scramble-siRNA vs. 
JNK1/2-siRNA, respectively) and Adhz63-infected cells (cell viability 45% vs. 
77% scramble-siRNA vs. JNK1/2-siRNA, respectively; Figure 19B). Using the 
same siRNA transfection approach, JNK1/2 suppression was also shown to 
inhibit the replication of all 3 Ads studied (Figure 19C). These differences were 
observed for all 3 Ads however, only Ad5- and Adhz63- infected cells displayed 
statistically significant differences between siRNA transfection groups. We found 
that 1.45 × 108 and 6.6 × 107 titers when transfected with scramble-siRNA, 




siRNA, respectively (Figure 19C). These data indicated that JNK expression 























Figure. 19 The effect of JNK expression upon A549 cell oncolysis and 
oncolytic Ad replication. (A) The concentration of JNK1/2-siRNA that efficiently 
repressed JNK1 and JNK2 expression was determined at 48 h by Western blot 




siRNA upon cell viability was assessed using crystal violet staining. Statistical 
analysis was performed by one-way ANOVA using Tukey’s post-test for multiple 
comparisons. (C) The effect of JNK1/2-siRNA upon Ad replication was assessed 
via the TCID50 method. Statistical analysis was performed by one-way ANOVA 
using Tukey’s post-test for multiple comparisons. † indicates p-value < 0.01, ‡ 


















4.4 – Discussion 
The goal of the studies in this chapter was to ascertain the relationship 
between Ads, p-JNK, Ad replication and oncolysis. Other laboratories have 
reported the requirement of JNK expression for the oncolytic effects of the E1b-
wild-type oncolytic Ad, Δ24RGD [81]. These findings were studied further by 
observing the effect of E1b upon JNK, specifically to understand why E1b-
deleted Ads produced disappointing results during clinical trials and to determine 
if p-JNK inducers can enhance the efficacy of Ad therapy. To my knowledge, this 
is the first report demonstrating the role of JNK to promote both Ad replication 
and oncolysis.  
During Ad infection, many cell death pathways are induced. However, 
several reports agree that autophagy is the predominant mechanism of cancer 
cell death induced following oncolytic Ad infection [55, 66, 78, 162-164]. In this 
report, significant induction of the autophagy marker LC3-II in A549 cells was 
observed following wild-type Ad5 infection beginning at 36 h post-infection 
(Figure 13C). The expression of p-JNK is known to induce autophagy via the 
phosphorylation of BCL-2, releasing BECLIN-1, which then initiates 
autophagosome formation [88, 151, 164]. Attenuated p-JNK induction by E1b-
deleted Ads was most pronounced following E1b55,19K-deleted Ad Adhz60 
infection relative to the E1b55K-deleted Ad Adhz63; indicating the importance of 
E1b-19K as a p-JNK inducer (Figure 15B). This finding is consistent with the only 
other known report describing E1b-mediated JNK phosphorylation [80]. In this 




This finding was confirmed using a selective E1b-19K expressing plasmid known 
as CMV-E1b19K [158]. These data indicated E1b-19K alone was sufficient to 
induce p-JNK production in A549 cells (Figure 15E).  
However, the E1b55,19K-deleted Ad Adhz60 induced p-JNK during Ad 
infection despite the loss of E1b, implicating the role of other non-E1b genes 
such as E1a to induce JNK phosphorylation (Figure 15B). Therefore, the 
E1b55K-deleted, CMV-E1a Ad Adhz69 [157] which overexpresses E1A was 
used to determine if increased E1A production stimulates greater JNK 
phosphorylation. These data indicated that E1a overexpression led to a marked 
increase in p-JNK production in A549 cells (Figure 16B). This is the first report, to 
my knowledge, to indicate that E1A induces JNK phosphorylation in cancer cells. 
To test if increased E1A production indirectly enhanced the expression of E1b-
19K, A549 cells were infected with Ad5, Adhz63, Adhz60, and Adhz69 and 
observed for the production of E1b-19K by Western blot analysis. These data 
indicated that Adhz69 displayed slightly greater levels of E1b-19K production 
(31.0 IOD) than the E1b55K-deleted Adhz63 (20.1 IOD; Figure 16B,C). 
Considering the subtle differences shown in E1b-19K expression, it is likely that 
the markedly enhanced p-JNK induction following Adhz69 treatment was due to 
increased E1A and not E1b-19K production. E1A, much like E1b-19K, does not 
have any endogenous kinase activity therefore it is likely that E1A induces JNK 
phosphorylation by the stimulation of the MAPK cascade or another family of 
kinases during infection. The effect of E1A upon JNK phosphorylation will be the 




Due to the important role of p-JNK during Ad oncolysis, cancer 
chemotherapeutics were screened for p-JNK production and observed their 
effects upon AdUV replication and oncolysis; AdUV was developed and 
characterized as described previously [82, 136]. These data indicated that 
etoposide was the greatest inducer of p-JNK production and was also shown to 
significantly enhance Ad oncolysis (p-value < 0.001; Figure 17C). For the first 
time, these data indicated that cancer chemotherapeutic drugs inducing p-JNK 
could enhance the therapeutic efficacy of oncolytic Ads. 
The use of pharmacological JNK phosphorylation inducers likely 
stimulated an array of other signaling pathways in addition to JNK, therefore 
additional approaches were necessary to further elucidate the effects of JNK 
upon Ad replication and oncolysis. To determine the effect of JNK upon Ad 
replication and oncolysis selectively, A549 cells were transfected with siRNA 
targeting identical mRNA sequences contained in both JNK1 and JNK2 mRNA 
[155, 156]. JNK1/2-siRNA transfected cells were shown to be partially protected 
against Ad-mediated A549 cell lysis (Figure 19B). These effects were more 
pronounced in the Ad5 and Adhz63 treatment groups. Ad5, Adhz63 and Adhz60 
replication was also suppressed in JNK1/2-siRNA relative to scramble-siRNA-
transfected cells. These data indicate the critical role of JNK to enhance Ad 
oncolysis and replication. 
In addition to inducing autophagic cancer cell death, p-JNK can also 
induce cancer cell growth. For example, A549 cells treated with the JNK1/2/3 




[165]. A549 cells are known to express k-RAS; the RAS pathway phosphorylates 
JNK indirectly via MKK7 of the MAPK cascade [166]. Unfortunately, there are 
very limited molecular tools to observe the selective effects of p-JNK upon 
autophagy without disrupting other important cellular processes such as cancer 
cell growth which play a significant role during Ad replication. Ads induce the 
cyclin E/CDK2 axis to induce an S-phase-like state in G0 cells during infection, 
increasing DNA synthesis in order to replicate Ad DNA [31, 33]. It is possible, 
therefore, that the inhibition of oncolytic Ad efficacy following JNK1/2-siRNA 
transfection could be the result of A549 cell cycle repression and not a direct 
effect of JNK upon Ad oncolysis.  
 These studies indicated for the first time that JNK not only supports Ad 
oncolysis, but also Ad replication. These data also indicate that Adhz69, an E1b-
19K wild-type E1a over-expressing Ad, was a highly efficient inducer of p-JNK 
production, implicating that E1A may play a significant role to induce JNK 
phosphorylation (Figure 16B). Cancer chemotherapeutics inducing p-JNK were 
also shown to enhance Ad oncolysis, supporting the role of p-JNK to enhance Ad 
oncolytic therapy (Figure 17C and 18A). The role of JNK to support Ad oncolysis 
were confirmed using JNK1/2-targeting siRNA; JNK suppression was also shown 
to inhibit Ad replication (Figure 19B,C). Previous reports indicate that autophagy 
inducers supported Ad oncolysis and replication [55, 66]. I have extended upon 
these studies and these data implicate p-JNK as an intriguing molecular target to 







SUMMARY AND FUTURE PERSPECTIVES 
 
All clinical studies conducted to date have shown that the efficacy of Ad 
oncolytic virotherapy has remained low [15, 17, 18, 57, 58, 98-100]. The 
disappointing efficacy of oncolytic Ads tested clinically appears to be due to 
many factors, including limited cancer cell lysis, inefficient Ad release from 
cancer cells, and spread in tumors [101-103]. Progress to improve the anti-
tumoral effects of Ads has been hampered by a lack of knowledge pertaining to 
which gene and mutations lead to enhanced Ad release and spread. 
Furthermore, the molecular mechanisms by which E1b-deleted oncolytic Ads 
induce oncolysis, specifically via autophagy and JNK phosphorylation are 
unknown. My goal was to fill these gaps and to obtain valuable information to 
enhance the cancer therapeutic efficacy of oncolytic Ads.  
Previously, oncolytic Ad spread was shown to be limited in solid tumors 
[35]; oncolytic Ads were shown to only infect of 5-20 tumor cells around the 
injection site following intratumoral injection [103]. In this dissertation, the 
oncolytic Ad mutant (AdUV) was developed. AdUV displayed enhanced release 
and spread. Upon DNA analysis, mutations which may have been responsible for 
enhanced AdUV release and spread may have been identified. These DNA 
mutations will be the subject of future experimentation. This dissertation also 




Ads phosphorylate JNK. Additionally the p-JNK inducer, etoposide, was shown to 
enhance the oncolytic effects of AdUV in vitro.   
Initial studies, shown in Chapter II, focused upon the development and 
characterization of the novel oncolytic Ad AdUV. Most Ads used in clinical 
studies have been subjected to E1 gene modifications to produce cancer 
selective Ad vectors. E1b-deleted Ads were shown to display attenuated 
oncolytic Ad replication, suppressing their therapeutic efficacy [96]. An alternative 
strategy to develop oncolytic Ads is to use random DNA mutagenesis and then 
select for Ad mutants with the desired therapeutic properties. In this dissertation, 
the E1 wild-type Ad, dl309 (Ad5) was repeatedly UV irradiated and selected in 
Soas-2 cells for 72 cycles. AdUV was then isolated from a large plaque clone 
formed on Soas-2 cells. After the characterization of 6 Ad large plaque forming 
clones, AdUV was shown to lyse cancer cells with the greatest efficiency and 
was studied further. AdUV was characterized and shown to lead to more efficient 
oncolysis compared to Ad5. This appeared to be related to enhanced autophagy 
induction and viral spread in vitro. (This paper has been published in Viruses 
2016, 8(6), 167; doi: 10.3390/v8060167). 
The work presented in Chapter III focused upon the investigation of those 
mutated genes in the AdUV genome. These mutations were thought to alter Ad 
oncolytic efficacy and therefore may be integrated into novel Ad vectors or 
combined with other approaches to develop next generation novel oncolytic Ads 
with enhanced cancer therapeutic efficacy. The Ad early genes in AdUV, E1a 




mutated. The mutations occurring within pV and its interaction partners IVa2 and 
pVIII, indicating the importance of these DNA packaging proteins for Ad 
oncolysis. Indirect evidence suggests that IVa2 and 33K can also form a complex 
with DNA-binding protein (DBP) on the 12 Ad capsid vertexes, facilitating Ad 
DNA packaging [110]. Additional mutations to pV and 52K also appear to have 
enhanced Ad DNA packaging via increasing the number of positively charged 
amino acids in these DNA binding proteins. To characterize the impact(s) of 
these mutations upon Ad replication and oncolysis, furher studies are needed to \ 
incorporate them into an Ad vector with well-characterized cancer selectivity.  
Additionally, the work presented in Chapter III indicated that AdUV 
suppressed A549 xenograft tumor growth and was non-lethal in nude mice. 
AdUV is an E1b wild-type Ad. E1b wild-type Ads displayed limited cancer 
therapeutic efficacy previously [138]. Therefore, the goal of this limited animal 
study to investigate whether these novel AdUV mutations were toxic to A549-
xenograft-bearing athymic nude mice (NCr-nu/nu). It is possible that the 
expression of E1b by AdUV could have also contributed to its enhanced oncolytic 
effects. Several other E1b wild-type oncolytic Ad vectors have been reported to 
display increased cancer therapeutic efficacy [81, 130]. Even though E1b 
expression is not essential for Ad replication in cancer cells [31], E1b may 
enhance Ad replication efficiency in cancer cells, likely via the induction of 
cyclinE [31] and autophagy [66]. Previously, E1b was shown to induce autophagy 
to provide the necessary macromolecules to promote Ad replication and 




well as the investigation of the interactions of Ads with autophagy mediators, may 
reveal additional therapeutic approaches to enhance oncolytic Ad therapy (This 
paper has been published in Viruses 2016, 8(12), 333; doi: 10.3390/v8120333). 
Chapter IV built upon the initial studies shown in Chapters II and III by 
evaluating p-JNK induction by E1b-deleted Ads in A549 cells. These studies also 
investigate the impact of p-JNK upon Ad replication and oncolysis. Previously p-
JNK was reported as an essential cellular factor for the oncolysis of E1b wild-
type Ads [88]; therefore the effect of JNK expression upon the replication and 
oncolysis of E1b wild-type and E1b-deleted Ads in A549 cells was evaluated via 
JNK1/2-siRNA suppression. These siRNA-JNK1/2 suppression studies indicated 
that JNK enhanced Ad replication and oncolysis in A549 cells. E1b-deleted Ads 
also displayed less p-JNK production in A549 cells. These differences were most 
pronounced between the E1b55K-deleted Adhz63 and the E1b55,19K-deleted 
Adhz60, indicating the importance of E1b-19K as a p-JNK inducer. This finding 
was validated using an E1b-19K plasmid expression vector. It also appears that 
the expression of E1A led to JNK phosphorylation. Increased E1a-mediated E1b-
19k transactivation may also play a minor role to induce p-JNK production as 
observed by Western blot analysis (This manuscript is in preparation). 
The work presented in this dissertation has addressed the question, “How 
can oncolytic Ad virotherapy be enhanced?” by generating a novel oncolytic Ad 
(AdUV) with enhanced anticancer efficacy, revealed DNA mutations which 
potentially could be utilized to create the next generation of oncolytic Ads, and 




implications for novel combinatorial cancer therapeutic development. This work 
also raises a number of interesting directions for future research in the field of 
oncolytic virotherapy. 
First, there is still much more to learn about the mutations and oncolytic 
properties of AdUV. These data indicate that AdUV contained several DNA 
mutations which may have contributed to its enhanced oncolytic efficiency, 
enhanced autophagy induction and release from A549 cells in vitro. DNA 
sequence analysis indicated that most of these mutations occurred in the Ad late 
genes, implicating their significance for the development of future oncolytic Ads. 
To determine which mutation(s), or combination of mutations, have the greatest 
effect upon oncolysis, additional in vitro and in vivo studies are necessary.  
Second, AdUV effectively suppressed A549 xenograft tumor growth while 
remaining non-lethal to athymic nude mice (NCr-nu/nu). Twelve of these 
mutations were shown to alter their respective encoded amino acid sequences. 
Six of these mutations were shown to occur in genes associated with Ad DNA 
packaging (Iva2, pTP, 33K, pV, 52K and pVIII). Two of these mutations, 52K and 
pV, replaced their encoded amino acids for positively charged residues. 
Therefore, I hypothesized that these mutations increased the ability of 52K and 
pV to bind the negatively charged DNA sugar-phosphate backbone more 
efficiently, leading to more rapid Ad release from infected cancer cells. I propose 
to incorporate these 52K and pV mutations into the E1b-deleted, cyclin E 
promoter driven E1A Ad, Ad-cycE as described previously [34, 35, 55]. These 




wild-type Ad5 was shown to be in-effective during clinical trials for cervical cancer 
in the 1950’s [138]. In addition to their limited anti-cancer efficacy, E1 wild-type 
Ads are no longer used in clinical studies due to their safety concerns and 
potential for cancer non-selective replication. For these reasons, E1 wild-type 
Ads such as AdUV are unlikely to be used in future clinical studies; however by 
the inclusion of these mutations into E1b-deleted vectors, such as Ad-cycE, the 
effects of these mutations can be further characterized and potentially be 
translated clinically. 
Third, the role of E1b-19K and E1a as inducers of JNK phosphorylation 
was elucidated in A549 cells. Interestingly, E1a-induced p-JNK may also be 
related to E1b19K via E1a-mediated, E1b-19K transactivation [40, 160]. Previous 
reports indicated that E1a alone was not sufficient to induce p-JNK production 
[80]. Therefore, the effects of E1a upon p-JNK in the absence of E1b-19K as well 
as the effects of E1a and E1b-19K plasmid co-transfection will be the subject of 
future studies. 
E1A effects many cellular pathways, however one of its most crucial roles 
is as a master regulator of viral and host cell gene transactivation. In this manner, 
E1A manipulates many cellular pathways to enhance Ad replication. It is also 
possible that E1A induces p-JNK by binding retinoblastoma protein (pRb), 
displacing the transcription factor E2F-1 from its pRb binding pocket, which then 
transactivates the expression of many autophagy-related genes including LC3 




p300 has been shown to form a multiprotein complex with CREB binding protein 
(CBP) and cyclic AMP dependent transcription factor (ATF2) protein to 
specifically bind the JUN2 element [170]. E1b wild-type Ads also induce 
autophagy independently of c-JUN expression [88]. This observation may be 
reconciled by the observation that JNK target sites on ATF2 were not required for 
the formation of the p300/CBP-ATF2 multi-protein complexes, indicating that p-
JNK and p300 act independently to induce c-JUN and autophagy [170]. JNK also 
participates in c-JUN-induced gene transactivation [171]. Therefore, it is also 
possible that p-JNK can enhance Ad gene transactivation in cooperation with c-
JNK to enhance Ad replication. In future studies, microarray and Ad serotype 5 
genomic analyses could identify novel c-JUN DNA binding sites to predict which 
Ad genes are affected by increased p-JNK production in cancer cells.  
To further understand the effect of p-JNK upon Ad replication and 
oncolysis, the use of chemical p-JNK inducers and siRNA mediated JNK 
suppression were utilizied. Etoposide was shown to induce p-JNK and enhance 
oncolysis, while inhibiting Ad replication. Another p-JNK inducer cycloheximide, 
was inhibited Ad oncolysis or replication of AdUV. I hypothesize these effects 
upon Ad replication may be related to the apoptosis induction by etoposide and 
the inhibition of protein synthesis by cycloheximide respectively [172]. These 
cancer chemotherapeutic drugs therefore may act upon p-JNK via a non-
selective mechanism of action. Therefore A549 cells were subjected to JNK1/2 
siRNA-mediated suppression. These data indicated that JNK enhanced AdUV 




replication and oncolysis, but the effects of JNK upon c-JUN, the transactivation 
of Ad genes and the licensing DNA replication machinery remains an interesting 
area for future research.  
These data indicate that p-JNK inducers are attractive molecular targets to 
enhance the anti-cancer therapeutic efficacy of oncolytic Ads. Another intriguing 
molecular target which has not been studied is the JNK phosphatase M3/6. M3/6 
selectively de-phosphorylates JNK; therefore, the inhibition of M3/6 would likely 
significantly enhance p-JNK production in a much more selective manner than 
cancer chemotherapeutics utilized in this study. The Dr. McMasters laboratory 
has confirmed that autophagy inducers acting via the cell starvation pathway 
enhanced oncolytic Ad replication and oncolysis. However these studies shown 
in Chapter IV indicate that autophagy inducers acting upon the p-JNK/BECLIN-1 
axis would produce greater synergistic cancer cell killing effects in combination 
with E1b-deleted oncolytic Ads than drugs targeting cell starvation induced 
autophagy [55, 66].  
These studies taken together have characterized the novel oncolytic Ad, 
AdUV, which displayed the therapeutic properties of enhanced oncolysis, 
release, spread and autophagy induction. Following DNA sequence analysis, the 
ability of AdUV to induce its enhanced cancer therapeutic effects appears related 
to mutations in the Ad late genes, specifically genes associated with Ad DNA 
packaging. This dissertation also provided a more complete description of the 
interaction between the E1 genes, JNK and Ad oncolysis. For the first time, a link 




targeting siRNA. There are many exciting future directions of these studies, 
including: the incorporation of AdUV DNA packaging gene mutations into well 
characterized oncolytic Ad vectors, the effect of JNK upon cyclin E, determining 
whether JNK is required for Ad-mediated DNA replication licensing, and finally, 
whether selective JNK induction enhances E1b-deleted Ad oncolysis. I believe 
that future progress in oncolytic adenovirology, along with various improvements 
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3MA   3-methyladenine 
Ad  Adenovirus 
Ad2  Adenovirus serotype 2 
Ad5  Adenovirus serotype 5 
Ads  Adenoviruses 
AEBSF 4-(2-aminoethyl)-benzenesulfonyl fluoride 
AMPK  AMP-activated protein kinase 
ANOVA Analysis of Variance 
AKT  Protein Kinase B 
ATF2  Cyclic AMP Dependent Transcription Factor  
Atg  Autophagy related 
BAL  Bronchoalveolar Lavage 
CFDA  China Food and Drug Administration 
ddH20  Double Distilled Water 
DMEM Dulbecco’s Modified Eagle Medium 




E1B  Early gene 1 B 
EC50  Effective Concentration 50% 
ECL  Enhanced Chemiluminescence 
FBS  Fetal Bovine Serum 
FDA  Food and Drug Administration 
GFP  Green Fluorescent Protien 
HRP  Horse Radish Peroxidase 
IFU  Infectious Viral Unit  
Ig  Immunoglobin 
IGV  Integrated Genomics Viewer 
IT  Intratumoral injection  
IV  Intravenous injection 
LB  Luria-Bertani broth 
LC3  Light Chain 3 
MAPK  Mitogen Activated Protein Kinase  
MOI  Multiplicity of Infection 
OD  Opitical Density or absorbance 
IOD  Integrated Optical Density 
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PI3K  Phosphoinositide 3-Kinase 
PI  Protease Inhibitor 
PML-nb Promyelocytic Leukemia ProteinNuclear Bodies 
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RIPA  Radioimmunoprecipitation Assay Buffer 
RPM  Revolutions Per Minute 
RPMI  Roswell Park Memorial Institute  
SC  Subcutaneous injection 
SDS  Sodium Dodecyl Sulfate 
SEER  Surveillance Epidemiology and End Results 
Ser  Serine 
TBST  Tris-Buffered saline with Tween 20 
TNM  Tumor Nodes Metastatsis 
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